Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Two or more vaccines in a single dosage form.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.
Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)
A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.
Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.
Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.
Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.
A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)
Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.
Immunoglobulins produced in response to VIRAL ANTIGENS.
A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.
A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.
Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.
Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).
Schedule giving optimum times usually for primary and/or secondary immunization.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.
Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.
Vaccines or candidate vaccines used to prevent ANTHRAX.
Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.
Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Any vaccine raised against any virus or viral derivative that causes hepatitis.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.
Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease.
A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)
Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.
Vaccines or candidate vaccines designed to prevent SAIDS; (SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME); and containing inactivated SIMIAN IMMUNODEFICIENCY VIRUS or type D retroviruses or some of their component antigens.
Vaccines or candidate vaccines used to prevent infection with SALMONELLA. This includes vaccines used to prevent TYPHOID FEVER or PARATYPHOID FEVER; (TYPHOID-PARATYPHOID VACCINES), and vaccines used to prevent nontyphoid salmonellosis.
Vaccines using supra-molecular structures composed of multiple copies of recombinantly expressed viral structural proteins. They are often antigentically indistinguishable from the virus from which they were derived.
Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.
An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.
Vaccines or candidate vaccines used to prevent infection with CYTOMEGALOVIRUS.
Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.
Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.
A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.
Vaccines used to prevent POLIOMYELITIS. They include inactivated (POLIOVIRUS VACCINE, INACTIVATED) and oral vaccines (POLIOVIRUS VACCINE, ORAL).
Delivery of medications through the nasal mucosa.
Vaccines or candidate vaccines used to prevent or treat both enterotoxigenic and enteropathogenic Escherichia coli infections.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Vaccines or candidate vaccines used to prevent infection with WEST NILE VIRUS.
Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.
Vaccines or candidate vaccines used to prevent bacillary dysentery (DYSENTERY, BACILLARY) caused by species of SHIGELLA.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.
Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals.
Antibody-mediated immune response. Humoral immunity is brought about by ANTIBODY FORMATION, resulting from TH2 CELLS activating B-LYMPHOCYTES, followed by COMPLEMENT ACTIVATION.
A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats.
Vaccines or candidate vaccines used to prevent infection by any virus from the family HERPESVIRIDAE.
The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer.
Vaccines or candidate vaccines used to prevent infection with LEISHMANIA.
A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.
A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 1 and neuraminidase 1. The H1N1 subtype was responsible for the Spanish flu pandemic of 1918.
Aluminum metal sulfate compounds used medically as astringents and for many industrial purposes. They are used in veterinary medicine for the treatment of ulcerative stomatitis, leukorrhea, conjunctivitis, pharyngitis, metritis, and minor wounds.
Vaccines or candidate vaccines used to prevent infection with viruses from the genus SIMPLEXVIRUS. This includes vaccines for HSV-1 and HSV-2.
Substances elaborated by bacteria that have antigenic activity.
The formaldehyde-inactivated toxin of Corynebacterium diphtheriae. It is generally used in mixtures with TETANUS TOXOID and PERTUSSIS VACCINE; (DTP); or with tetanus toxoid alone (DT for pediatric use and Td, which contains 5- to 10-fold less diphtheria toxoid, for other use). Diphtheria toxoid is used for the prevention of diphtheria; DIPHTHERIA ANTITOXIN is for treatment.
Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.
Protection conferred on a host by inoculation with one strain or component of a microorganism that prevents infection when later challenged with a similar strain. Most commonly the microorganism is a virus.
Vaccines or candidate vaccines used to prevent infection with Japanese B encephalitis virus (ENCEPHALITIS VIRUS, JAPANESE).
Administration of a vaccine to large populations in order to elicit IMMUNITY.
Vaccines or candidate vaccines used to prevent conception.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
Vaccines or candidate vaccines derived from edible plants. Transgenic plants (PLANTS, TRANSGENIC) are used as recombinant protein production systems and the edible plant tissue functions as an oral vaccine.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.
Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
The relationship between an elicited ADAPTIVE IMMUNE RESPONSE and the dose of the vaccine administered.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM.
Vaccines for the prevention of diseases caused by various species of Rickettsia.
An acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide. (Dorland, 28th ed)
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
Vaccines or candidate vaccines used to prevent infection with parainfluenza viruses in humans and animals.
Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IMMUNOGLOBULIN A, SECRETORY) that serves to protect these ports of entry into the body.
Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.
A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 5 and neuraminidase 1. The H5N1 subtype, frequently referred to as the bird flu virus, is endemic in wild birds and very contagious among both domestic (POULTRY) and wild birds. It does not usually infect humans, but some cases have been reported.
A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 3 and neuraminidase 2. The H3N2 subtype was responsible for the Hong Kong flu pandemic of 1968.
Species of the genus INFLUENZAVIRUS B that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed.
Vaccines or candidate vaccines used to prevent PSEUDORABIES (Aujeszky's disease), a herpesvirus of swine and other animals.
A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans.
The type species of ORTHOPOXVIRUS, related to COWPOX VIRUS, but whose true origin is unknown. It has been used as a live vaccine against SMALLPOX. It is also used as a vector for inserting foreign DNA into animals. Rabbitpox virus is a subspecies of VACCINIA VIRUS.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)
The process of keeping pharmaceutical products in an appropriate location.
Substances elaborated by viruses that have antigenic activity.
Acute VIRAL CNS INFECTION affecting mammals, including humans. It is caused by RABIES VIRUS and usually spread by contamination with virus-laden saliva of bites inflicted by rabid animals. Important animal vectors include the dog, cat, bat, fox, raccoon, skunk, and wolf.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
Virus diseases caused by the ORTHOMYXOVIRIDAE.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
Proteins found in any species of protozoan.
The type species of the genus INFLUENZAVIRUS A that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces.
Infections with bacteria of the species NEISSERIA MENINGITIDIS.
Vaccines used in conjunction with diagnostic tests to differentiate vaccinated animals from carrier animals. Marker vaccines can be either a subunit or a gene-deleted vaccine.
A type of H. influenzae isolated most frequently from biotype I. Prior to vaccine availability, it was a leading cause of childhood meningitis.
Process of determining and distinguishing species of bacteria or viruses based on antigens they share.
The type species of the FLAVIVIRUS genus. Principal vector transmission to humans is by AEDES spp. mosquitoes.
Strains of Neisseria meningitidis which are the most common ones causing infections or disease in infants. Serogroup B strains are isolated most frequently in sporadic cases, and are less common in outbreaks and epidemics.
The non-susceptibility to infection of a large group of individuals in a population. A variety of factors can be responsible for herd immunity and this gives rise to the different definitions used in the literature. Most commonly, herd immunity refers to the case when, if most of the population is immune, infection of a single individual will not cause an epidemic. Also, in such immunized populations, susceptible individuals are not likely to become infected. Herd immunity can also refer to the case when unprotected individuals fail to contract a disease because the infecting organism has been banished from the population.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Vaccines or candidate vaccines used to prevent LYME DISEASE.
An acute infectious disease caused by RUBULAVIRUS, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. (From Dorland, 28th ed)
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS.
A disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. Localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. It may progress to the generalized form.
The expelling of virus particles from the body. Important routes include the respiratory tract, genital tract, and intestinal tract. Virus shedding is an important means of vertical transmission (INFECTIOUS DISEASE TRANSMISSION, VERTICAL).
Epidemics of infectious disease that have spread to many countries, often more than one continent, and usually affecting a large number of people.
Vaccines or candidate vaccines used to prevent or treat PSEUDOMONAS INFECTIONS.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins.
The giving of drugs, chemicals, or other substances by mouth.
A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8)
Antibodies reactive with HIV ANTIGENS.
Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.
A localized infection of mucous membranes or skin caused by toxigenic strains of CORYNEBACTERIUM DIPHTHERIAE. It is characterized by the presence of a pseudomembrane at the site of infection. DIPHTHERIA TOXIN, produced by C. diphtheriae, can cause myocarditis, polyneuritis, and other systemic toxic effects.
The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.
A species of gram-negative, aerobic bacteria that is the causative agent of WHOOPING COUGH. Its cells are minute coccobacilli that are surrounded by a slime sheath.
Antigenic determinants recognized and bound by the B-cell receptor. Epitopes recognized by the B-cell receptor are located on the surface of the antigen.
A method of detection of the number of cells in a sample secreting a specific molecule. With this method, a population of cells are plated over top of the immunosorbent substrate that captures the secreted molecules.
A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics.
Viruses containing two or more pieces of nucleic acid (segmented genome) from different parents. Such viruses are produced in cells coinfected with different strains of a given virus.
Techniques where DNA is delivered directly into organelles at high speed using projectiles coated with nucleic acid, shot from a helium-powered gun (gene gun). One of these techniques involves immunization by DNA VACCINES, which delivers DNA-coated gold beads to the epidermis.
A CELL LINE derived from the kidney of the African green (vervet) monkey, (CERCOPITHECUS AETHIOPS) used primarily in virus replication studies and plaque assays.
Elements of limited time intervals, contributing to particular results or situations.
The type species of LYSSAVIRUS causing rabies in humans and other animals. Transmission is mostly by animal bites through saliva. The virus is neurotropic multiplying in neurons and myotubes of vertebrates.
A genus of REOVIRIDAE, causing acute gastroenteritis in BIRDS and MAMMALS, including humans. Transmission is horizontal and by environmental contamination. Seven species (Rotaviruses A thru G) are recognized.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Proteins isolated from the outer membrane of Gram-negative bacteria.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
Proteins found in any species of bacterium.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Infections with bacteria of the genus HAEMOPHILUS.
A species of CERCOPITHECUS containing three subspecies: C. tantalus, C. pygerythrus, and C. sabeus. They are found in the forests and savannah of Africa. The African green monkey (C. pygerythrus) is the natural host of SIMIAN IMMUNODEFICIENCY VIRUS and is used in AIDS research.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
A highly contagious infectious disease caused by the varicella-zoster virus (HERPESVIRUS 3, HUMAN). It usually affects children, is spread by direct contact or respiratory route via droplet nuclei, and is characterized by the appearance on the skin and mucous membranes of successive crops of typical pruritic vesicular lesions that are easily broken and become scabbed. Chickenpox is relatively benign in children, but may be complicated by pneumonia and encephalitis in adults. (From Dorland, 27th ed)
An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.
Semidomesticated variety of European polecat much used for hunting RODENTS and/or RABBITS and as a laboratory animal. It is in the subfamily Mustelinae, family MUSTELIDAE.
The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
The application of scientific knowledge or technology to pharmacy and the pharmaceutical industry. It includes methods, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and storing of drugs and other preparations used in diagnostic and determinative procedures, and in the treatment of patients.
Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
Established cell cultures that have the potential to propagate indefinitely.
Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).
An infant during the first month after birth.
Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS.
A serotype of SALMONELLA ENTERICA which is the etiologic agent of TYPHOID FEVER.
Preparations of pathogenic organisms or their derivatives made nontoxic and intended for active immunologic prophylaxis. They include deactivated toxins. Anatoxin toxoids are distinct from anatoxins that are TROPANES found in CYANOBACTERIA.
Vaccines used to prevent infection by any virus from the family ADENOVIRIDAE.
A family of RNA viruses causing INFLUENZA and other diseases. There are five recognized genera: INFLUENZAVIRUS A; INFLUENZAVIRUS B; INFLUENZAVIRUS C; ISAVIRUS; and THOGOTOVIRUS.
A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases.
Vaccines or candidate vaccines used to prevent or treat ALZHEIMER DISEASE.
Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV.
A species of the genus FLAVIVIRUS which causes an acute febrile and sometimes hemorrhagic disease in man. Dengue is mosquito-borne and four serotypes are known.
A highly fatal, acute hemorrhagic fever, clinically very similar to MARBURG VIRUS DISEASE, caused by EBOLAVIRUS, first occurring in the Sudan and adjacent northwestern (what was then) Zaire.
An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.
Proteins prepared by recombinant DNA technology.
The type species of MORBILLIVIRUS and the cause of the highly infectious human disease MEASLES, which affects mostly children.

Potential advantages of DNA immunization for influenza epidemic and pandemic planning. (1/2315)

Immunization with purified DNA is a powerful technique for inducing immune responses. The concept of DNA immunization involves insertion of the gene encoding the antigen of choice into a bacterial plasmid and injection of the plasmid into the host where the antigen is expressed and where it induces humoral and cellular immunity. The most effective routes and methods for DNA immunization are bombardment with particles coated with DNA ("gene gun" technique), followed by the intramuscular and intradermal routes. DNA immunization technology has the potential to induce immunity to all antigens that can be completely encoded in DNA, which therefore include all protein, but not carbohydrate, antigens. DNA immunization results in presentation of antigens to the host's immune system in a natural form, like that achieved with live-attenuated vaccines. The DNA immunization strategy has the potential to rapidly provide a new vaccine in the face of an emerging influenza pandemic.  (+info)

Non-coding plasmid DNA induces IFN-gamma in vivo and suppresses autoimmune encephalomyelitis. (2/2315)

Regulatory sequences used in plasmids for naked DNA vaccination can modulate cytokine production in vivo. We demonstrate here that injection of plasmid DNA can suppress the prototypic T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis, by inducing IFN-gamma.  (+info)

DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection. (3/2315)

Seoul virus (SEOV) is one of four known hantaviruses causing hemorrhagic fever with renal syndrome (HFRS). Candidate naked DNA vaccines for HFRS were constructed by subcloning cDNA representing the medium (M; encoding the G1 and G2 glycoproteins) or small (S; encoding the nucleocapsid protein) genome segment of SEOV into the DNA expression vector pWRG7077. We vaccinated BALB/c mice with three doses of the M or S DNA vaccine at 4-week intervals by either gene gun inoculation of the epidermis or needle inoculation into the gastrocnemius muscle. Both routes of vaccination resulted in antibody responses as measured by ELISA; however, gene gun inoculation elicited a higher frequency of seroconversion and higher levels of antibodies in individual mice. We vaccinated Syrian hamsters with the M or S construct using the gene gun and found hantavirus-specific antibodies in five of five and four of five hamsters, respectively. Animals vaccinated with the M construct developed a neutralizing antibody response that was greatly enhanced in the presence of guinea pig complement. Immunized hamsters were challenged with SEOV and, after 28 days, were monitored for evidence of infection. Hamsters vaccinated with M were protected from infection, but hamsters vaccinated with S were not protected.  (+info)

IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. (4/2315)

IL-12 has been shown to enhance cellular immunity in vitro and in vivo. Recent reports have suggested that combining DNA vaccine approach with immune stimulatory molecules delivered as genes may significantly enhance Ag-specific immune responses in vivo. In particular, IL-12 molecules could constitute an important addition to a herpes vaccine by amplifying specific immune responses. Here we investigate the utility of IL-12 cDNA as an adjuvant for a herpes simplex virus-2 (HSV-2) DNA vaccine in a mouse challenge model. Direct i.m. injection of IL-12 cDNA induced activation of resting immune cells in vivo. Furthermore, coinjection with IL-12 cDNA and gD DNA vaccine inhibited both systemic gD-specific Ab and local Ab levels compared with gD plasmid vaccination alone. In contrast, Th cell proliferative responses and secretion of cytokines (IL-2 and IFN-gamma) and chemokines (RANTES and macrophage inflammatory protein-1alpha) were significantly increased by IL-12 coinjection. However, the production of cytokines (IL-4 and IL-10) and chemokine (MCP-1) was inhibited by IL-12 coinjection. IL-12 coinjection with a gD DNA vaccine showed significantly better protection from lethal HSV-2 challenge compared with gD DNA vaccination alone in both inbred and outbred mice. This enhanced protection appears to be mediated by CD4+ T cells, as determined by in vivo CD4+ T cell deletion. Thus, IL-12 cDNA as a DNA vaccine adjuvant drives Ag-specific Th1 type CD4+ T cell responses that result in reduced HSV-2-derived morbidity as well as mortality.  (+info)

Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. (5/2315)

The potential roles of adhesion molecules in the expansion of T cell-mediated immune responses in the periphery were examined using DNA immunogen constructs as model antigens. We coimmunized cDNA expression cassettes encoding the adhesion molecules intracellular adhesion molecule-1 (ICAM-1), lymphocyte function associated-3 (LFA-3), and vascular cell adhesion molecule-1 (VCAM-1) along with DNA immunogens, and we analyzed the resulting antigen-specific immune responses. We observed that antigen-specific T-cell responses can be enhanced by the coexpression of DNA immunogen and adhesion molecules ICAM-1 and LFA-3. Coexpression of ICAM-1 or LFA-3 molecules along with DNA immunogens resulted in a significant enhancement of T-helper cell proliferative responses. In addition, coimmunization with pCICAM-1 (and more moderately with pCLFA-3) resulted in a dramatic enhancement of CD8-restricted cytotoxic T-lymphocyte responses. Although VCAM-1 and ICAM-1 are similar in size, VCAM-1 coimmunization did not have any measurable effect on cell-mediated responses. These results suggest that ICAM-1 and LFA-3 provide direct T-cell costimulation. These observations are further supported by the finding that coinjection with ICAM-1 dramatically enhanced the level of interferon-gamma (IFN-gamma) and beta-chemokines macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and regulated on activation normal T-cell expression and secreted (RANTES) produced by stimulated T cells. Through comparative studies, we observed that ICAM-1/LFA-1 T-cell costimulatory pathways are independent of CD86/CD28 pathways and that they may synergistically expand T-cell responses in vivo.  (+info)

Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. (6/2315)

Immunological intervention, in addition to vector control and malaria chemotherapy, will be needed to stop the resurgence of malaria, a disease with a devastating impact on the health of 300 to 500 million people annually. We have pursued a vaccination strategy, based on DNA immunization in mice with genes encoding two antigens present on the sexual stages of Plasmodium falciparum, Pfs25 and Pfg27, to induce biologically important antibodies that can block development of the parasite in the Anopheles mosquito and thus transmission of the disease. DNA encoding Pfs25 when administered by the intramuscular route, either alone or with DNA encoding Pfg27, had the most potent transmission-blocking effects, resulting in up to a 97% decrease in oocyst numbers in mosquito midguts and a 75% decrease in rate of infection. Immunization with DNA encoding a Pfg27-Pfs25 fusion protein was less effective and DNA encoding Pfg27 elicited antibodies in sera that had only modest effects on the infectivity of the parasite. These results show for the first time that DNA vaccination can result in potent transmission-blocking antibodies in mice and suggest that the Pfs25 gene should be included as part of a multicomponent DNA vaccine.  (+info)

Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. (7/2315)

The development of more-effective antituberculosis vaccines would assist in the control of the global problem of infection with Mycobacterium tuberculosis. One recently devised vaccination strategy is immunization with DNA plasmids encoding individual microbial genes. Using the genes for the M. tuberculosis secreted proteins MPT64 (23 kDa), Ag85B (30 kDa), and ESAT-6 (6 kDa) as candidate antigens, DNA vaccines were prepared and tested for immunogenicity and protective efficacy in a murine model of aerosolized tuberculosis (TB). Intramuscular immunization with DNA-64 or DNA-85B resulted in the activation of CD4(+) T cells, which produce gamma interferon (IFN-gamma), and high titers of specific immunoglobulin G antibodies. Further, DNA-64 induced major histocompatibility complex class I-restricted CD8(+) cytotoxic T cells. The addition of a eukaryotic leader sequence to mpt64 did not significantly increase the T-cell or antibody response. Each of the three DNA vectors stimulated a significant reduction in the level of M. tuberculosis infection in the lungs of mice challenged 4 weeks after immunization, but not to the levels resulting after immunization with Mycobacterium bovis BCG. The vaccines showed a consistent hierarchy of protection, with the most effective being Ag85B, followed by ESAT-6 and then MPT64. Coimmunization with the three vectors resulted in a greater degree of protection than that induced by any single vector. This protective efficacy was associated with the emergence of IFN-gamma-secreting T cells earlier than in infected animals immunized with a control vector. The efficacy of these DNA vaccines suggests that multisubunit vaccination may contribute to future vaccine strategies against TB.  (+info)

Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. (8/2315)

Usually we rely on vaccination to promote an immune response to a pathogenic microbe. In this study, we demonstrate a suppressive from of vaccination, with DNA encoding a minigene for residues 139-151 of myelin proteolipid protein (PLP139-151), a pathogenic self-Ag. This suppressive vaccination attenuates a prototypic autoimmune disease, experimental autoimmune encephalomyelitis, which presents clinically with paralysis. Proliferative responses and production of the Th1 cytokines, IL-2 and IFN-gamma, were reduced in T cells responsive to PLP139-151. In the brains of mice that were successfully vaccinated, mRNA for IL-2, IL-15, and IFN-gamma were reduced. A mechanism underlying the reduction in severity and incidence of paralytic autoimmune disease and the reduction in Th1 cytokines involves altered costimulation of T cells; loading of APCs with DNA encoding PLP139-151 reduced the capacity of a T cell line reactive to PLP139-151 to proliferate even in the presence of exogenous CD28 costimulation. DNA immunization with the myelin minigene for PLP-altered expression of B7.1 (CD80), and B7.2 (CD86) on APCs in the spleen. Suppressive immunization against self-Ags encoded by DNA may be exploited to treat autoimmune diseases.  (+info)

Dennis Thompson, HealthDay News An experimental DNA-based vaccine protected monkeys from infection with the Zika virus, and it has proceeded to human safety trials, researchers report.
New York, March 26 Creative Biolabs, a leading pre-clinical vaccine development and production company, now offers safe and efficacious nucleic acid vaccines, that is, DNA and RNA vaccine.. As a professional, Creative Biolabs has effectively supported the vaccine industry for decades with a full range of vaccine design and production services and related products. We combine the traditional and the most updated genetic engineering technologies to efficiently produce highly immunogenic vaccines addressing urgent unmet medical needs.. A vaccine is a biological agent that provides active acquired immunity to a particular disease and usually contains an agent that resembles a disease-causing microorganism. In contrast to recombinant bacteria or virus vaccines, nucleic acid vaccines consist only of DNA or RNA, which is uptake by cells and transformed into protein, protecting against disease by injection with genetically engineered DNA (as a plasmid) or RNA (as mRNA). Their immunogenicity and efficacy ...
Our previous studies have shown that therapeutic DNA vaccine induction of mucosal responses correlated with significant reduction of virus in the gut of SIV-inf...
TY - JOUR. T1 - Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell. AU - Kim, Daejin. AU - Hoory, Talia. AU - Wu, T. C.. AU - Hung, Chien Fu. PY - 2007/11/1. Y1 - 2007/11/1. N2 - Intradermal administration of DNA vaccines, using a gene gun, represents an effective means of delivering DNA directly into professional antigen-presenting cells (APCs) in the skin and thus allows the application of strategies to modify the properties of APCs to enhance DNA vaccine potency. In the current study, we hypothesized that the potency of human papillomavirus (HPV) type 16 E7 DNA vaccines employing intracellular targeting strategies combined with a strategy to prolong the life of dendritic cells (DCs) could be further enhanced by the addition of a DNA vaccine capable of generating high numbers of pan-HLA-DR reactive epitope (PADRE)-specific CD4+ T cells. We observed that the addition of PADRE DNA to E7 ...
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
Due to their rapid and widespread development, DNA vaccines have entered into a variety of human clinical trials for vaccines against various diseases including cancer. Evidence that DNA vaccines are well tolerated and have an excellent safety profile proved to be of advantage as many clinical trials combines the first phase with the second, saving both time and money. It is clear from the results obtained in clinical trials that such DNA vaccines require much improvement in antigen expression and delivery methods to make them sufficiently effective in the clinic. Similarly, it is clear that additional strategies are required to activate effective immunity against poorly immunogenic tumor antigens. Engineering vaccine design for manipulating antigen presentation and processing pathways is one of the most important aspects that can be easily handled in the DNA vaccine technology. Several approaches have been investigated including DNA vaccine engineering, co-delivery of immunomodulatory molecules, safe
DNA vaccines have progressed rapidly from the conceptual stage to the stage of clinical trials. While studies in small laboratory animals have shown great promise, initial reports from human studies were less encouraging. Progress is being made, however, documented by the papers presented here. This volume contains the proceedings of a meeting devoted to the latest developments in DNA vaccines, from laboratory studies to clinical trials. The papers, written by leaders in the field, focus on the current state of DNA vaccines in humans and other large animals. The bulk of the studies involve DNA vaccines against HIV/SIV. Other promising trials make use of DNA vaccines against malaria and hepatitis B. The papers inform the reader about the immune basis of this form of vaccination and about approaches being developed to increase the efficacy of DNA vaccines in humans. These include the co-administration of cytokines, prime-boost strategies, optimising codon usage or the use of CpG motifs. An ...
The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein. The engineered construct, INO-4800, results in robust expression of the S protein in vitro. Following immunization of mice and guinea pigs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize the SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to the lungs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, ...
This topic contains 2 study abstracts on Vaccination: Plasmid DNA Vaccines indicating they may negatively impact Infertility, Vaccination: Abortion, and Vaccine-induced Toxicity
CCL2 DNA vaccines are directed against the host chemoattractant molecule CCL2 (MCP-1), a key chemokine in recruiting macrophages to sites of inflammation. Macrophages recruited by CCL2 lead to progressive renal injury. In rat models of disease unmodified CCL2 DNA vaccine in combination with a CCL5 (RANTES) DNA vaccine can protect against chronic renal disease. The mechanism of protection involves the induction of auto-antibodies to the CCL2. Introduction of the adjuvant p-tet into the DNA structure of the CCL2 vaccine leads to enhanced potency with the induction of specific Th1 cellular immunity. The strategies outlined here demonstrate a model for developing potent vaccines against highly restricted self targets.
In addition to the general medical benefits, DNA vaccines can provide a large economic benefit. Due to the decreased restrictions in the production and storage of DNA vaccines compared to regular vaccines, the cost of producing and maintaining DNA vaccines is much lower. This can be especially beneficial to people in developing countries. According to certain case studies, the cost of developing and manufacturing a successful and beneficial conventional vaccine can range from $500 million to $1 billion. Comparatively, the development and manufacturing of a DNA vaccine ranges between $200 and $300 million ...
A novel DNA vaccine vector encoding the Mycobacterium tuberculosis secreted antigen Ag85A fused with the influenza A virus (IAV) HA2 protein epitopes, pEGFP/Ag85A-sHA2 (pAg85A-sHA2), was designed to provide protection against influenza. The antigen encoded by the DNA vaccine vector was efficiently expressed in mammalian cells, as determined by reverse transcription polymerase chain reaction (RT-PCR) and fluorescence analyses. Mice were immunized with the vaccine vector by intramuscular injection before challenge with A/Puerto Rico/8/34 virus (PR8 virus). Sera and the splenocyte culture IFN-γ levels were significantly higher in immunized mice compared with the control mice. The novel vaccine group showed a high neutralization antibody titer in vitro. The novel vaccine vector also reduced the viral loads, increased the survival rates in mice after the PR8 virus challenge and reduced the alveolar inflammatory cell numbers. Sera IL-4 concentrations were significantly increased in mice immunized with the
Nucleic acid vaccines, like other biotechnology derived vaccines, will be evaluated on a case-by-case basis. Evaluation of vaccine master seeds is an essential first step for fulfilling these requirements.
T. gondii is an important zoonotic Apicomplexan parasite, but no drugs could eliminate the pathogen from the host effectively. In recent studies, DNA vaccines have shown the potential to defend against T. gondii infection in view of their abilities to induce long-term humoral and cellular immune responses in animal models. Many rhoptry proteins (ROP5, ROP13, ROP16 and ROP18) [16-19] are identified to be potential candidates for development of T. gondii DNA vaccines. TgROP38, a new member of the rhoptry protein family, was firstly identified by the phylogenomic approach and was found to regulate the expression of host transcription factors, signaling pathways and cell proliferation, and apoptosis that sum up about 1200 host genes [21]. These key biological roles of TgROP38 in T. gondii infection of the host have stimulated us to evaluate whether TgROP38 could elicit effective immune responses against infection with T. gondii in the mice model. Therefore, we constructed the recombinant plasmid ...
The spleens of intramuscularly or gene gun immunized mice enlarged notably compared with those of the unimmunized controls. In particular, the spleen weight of the gene gun injected mice almost doubled that of the unimmunized controls (data not shown). FACS analysis of spleen cells harvested 2 weeks after the final immunization with AMA-1 or AMA-1 plus IL-12 DNA vaccines showed notable differences in the proportions of CD4+ and CD8+ T-lymphocytes between the intramuscular injection versus the gene gun (epidermis) injection (Fig. 2). In mice immunized intramuscularly (n=5 for each group) with AMA-1 alone or AMA-1 plus IL-12 DNA vaccines, the proportions of T-cell subsets (17.9±0.47% or 15.5±0.79% for CD8+ T-cells and 27.6±0.84% or 27.7±0.72% for CD4+ T-cells) did not show any significant changes (P,0.05), compared with control mice immunized only with UB vector (16.2±0.78% for CD8+ T-cells and 26.5±0.35% for CD4+ T-cells) (Fig. 2). By contrast, in mice injected with a gene gun (n=3 for each ...
The effectiveness of a vaccine may be increased when combined with an adjuvant and/or when given with EP. The addition of an adjuvant or EP may increase a persons immune response to a vaccine. Furthermore, the immune response to HIV antigens may be improved by giving a DNA vaccine boosted with a live vector vaccine. The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV DNA vaccine (HIV-MAG) alone or in combination with an IL-12 pDNA adjuvant, delivered IM via EP followed by a Vesicular Stomatitis Virus (VSV) HIV gag vaccine boost given IM by needle and syringe in healthy, HIV-uninfected adults.. Participants will be enrolled into the study in one of four groups. Each of the four groups will receive 3 mg of the HIV-MAG vaccine alone or combined with one of three different doses of the IL-12 pDNA adjuvant, followed by the VSV HIV gag vaccine boost. Within each of the four groups, participants will be randomly assigned to receive the study vaccines or ...
The effectiveness of a vaccine may be increased when combined with an adjuvant and/or when given with EP. The addition of an adjuvant or EP may increase a persons immune response to a vaccine. Furthermore, the immune response to HIV antigens may be improved by giving a DNA vaccine boosted with a live vector vaccine. The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV DNA vaccine (HIV-MAG) alone or in combination with an IL-12 pDNA adjuvant, delivered IM via EP followed by a Vesicular Stomatitis Virus (VSV) HIV gag vaccine boost given IM by needle and syringe in healthy, HIV-uninfected adults.. Participants will be enrolled into the study in one of four groups. Each of the four groups will receive 3 mg of the HIV-MAG vaccine alone or combined with one of three different doses of the IL-12 pDNA adjuvant, followed by the VSV HIV gag vaccine boost. Within each of the four groups, participants will be randomly assigned to receive the study vaccines or ...
Developing vaccines for the prevention of human infection by H5N1 influenza viruses is an urgent task. DNA vaccines are a novel alternative to conventional vaccines and should contribute to the prophylaxis of emerging H5N1 virus. In this study, we assessed whether a single immunization with plasmid DNA expressing H5N1 hemagglutinin (HA) could provide early protection against lethal challenge in a mouse model. Mice were immunized once with HA DNA at 3, 5, 7 days before a lethal challenge. The survival rate, virus titer in the lungs and change of body weight were assayed to evaluate the protective abilities of the vaccine. To test the humoral immune response induced by HA DNA, serum samples were collected through the eye canthus of mice on various days after immunization and examined for specific antibodies by ELISA and an HI assay. Splenocytes were isolated after the immunization to determine the antigen-specific T-cell response by the ELISPOT assay. Challenge experiments revealed that a single
DNA vaccination is a technique for protecting against disease by injection with genetically engineered DNA so cells directly produce an antigen, producing a protective immunological response. DNA vaccines have potential advantages over conventional vaccines, including the ability to induce a wider range of immune response types. Several DNA vaccines are available for veterinary use. Currently no DNA vaccines have been approved for human use. Research is investigating the approach for viral, bacterial and parasitic diseases in humans, as well as for several cancers. Vaccines have eliminated naturally occurring smallpox, and nearly eliminated polio, while other diseases, such as typhus, rotavirus, hepatitis A and B and others are well controlled. Conventional vaccines cover a small number of diseases, while other infections kill millions of people every year. First generation vaccines are whole-organism vaccines - either live and weakened, or killed forms. Live, attenuated vaccines, such as ...
To further improve fertility of animals, a novel gene RFRP-3 (RF-amide related peptide-3,RFRP-3) was used to construct DNA vaccines with INH α (1-32) (inhibin, IN...
DNA vaccination holds great promise for the prevention and treatment of cancer and infectious diseases. However, the clinical ability of DNA vaccines is still controversial due to the limited immune response initially observed in humans. We hypothesized that electroporation of a plasmid encoding the HIV-1 Gag viral capsid protein would enhance cancer DNA vaccine potency. DNA electroporation used to deliver plasmids in vivo, induced type I interferons, thereby supporting the activation of innate immunity. The coadministration of ovalbumin (OVA) and HIV-1 Gag encoding plasmids modulated the adaptive immune response. This strategy favored antigen-specific Th1 immunity, delayed B16F10-OVA tumor growth and improved mouse survival in both prophylactic and therapeutic vaccination approaches. Similarly, a prophylactic DNA immunization against the melanoma-associated antigen gp100 was enhanced by the codelivery of the HIV-1 Gag plasmid. The adjuvant effect was not driven by the formation of HIV-1 Gag ...
Scientists have developed a novel method for delivering therapeutic molecules into cells. The method harnesses gold nanoparticles that are electrically activated, causing them to oscillate and bore holes in cells outer membranes and allowing key molecules - such as DNA, RNA, and proteins - to gain entry.
Abstract Autophagy plays an important role in neoplastic transformation of cells and in resistance of cancer cells to radio and chemotherapy. p62 (SQSTM1) is a key component of autophagic machinery which is also involved in signal transduction. Although recent empirical observations demonstrated that p62 is overexpressed in variety of human tumors, a mechanism of p62 overexpression is not known. Here we report that the transformation of normal human mammary epithelial cells with diverse oncogenes (RAS, PIK3CA and Her2) causes marked accumulation of p62. Based on this result, we hypothesized that p62 may be a feasible candidate to be an anti- cancer DNA vaccine. Here we performed a preclinical study of a novel DNA vaccine encoding p62. Intramuscularly administered p62-encoding plasmid induced anti-p62 antibodies and exhibited strong antitumor activity in three models of allogeneic mouse tumors - B16 melanoma, Lewis lung carcinoma (LLC), and S37 sarcoma. P62-encoding plasmid has demonstrated its ...
In this work, we report the evaluation of two DNA vaccines against dengue-3 virus (DENV-3). The first construction, called pVAC3DEN3, was engineered inserting the pre-membrane (prM) and envelope (E) gene of DENV-3 truncated with a restriction site between them, as previously described. The second construction was developed cloning the full gene sequence of prM and E from DENV-3 virus in pCI plasmid for mammalian expression and was denominated pVAC1WDEN3. The results showed that both constructions were capable of expressing the prM and E proteins, as demonstrated by ELISA and immunoblotting detection in cell culture transfected with the plasmids. After positive
PowderMed Ltd. (a subsidiary of Pfizer) was developing a therapeutic DNA vaccine for the treatment of genital warts caused by the human papillomavirus (HPV).
With increasing prophylactic HPV vaccination rates among the general population and the expansion of FDA approval for vaccination of all age groups, the rates of HPV infection and subsequent malignancy are set to drop over the coming decades.3 27 There remains, however, an unmet need for an HPV therapeutic vaccine. Currently, there are over 10 HPV therapeutic vaccines under development, and in various stages of clinical testing, but mostly in phase I or II.11 Vaccines are being developed employing multiple platforms, including DNA, bacterial and viral vectors, peptides and proteins. VGX-3100 is an HPV 16/18 DNA-based vaccine that is administered intramuscularly via electroporation, and is currently being tested in a phase III trial (NCT03721978) for high-grade cervical lesions, CIN2/3, which are a direct precursor to cervical cancer. AXAL-CERV is a Listeria monocytogenes-based vaccine currently in a phase III clinical trial to treat patients with high risk locally advanced cervical cancer (NCT ...
Influenza is one of the most important illnesses in the modern world, causing great public health losses each year due to the lack of medication and broadly protective, long-lasting vaccines. The development of highly immunogenic and safe vaccines is currently one of the major problems encountered in efficient influenza prevention. DNA vaccines represent a novel and powerful alternative to the conventional vaccine approaches. To improve the efficacy of the DNA vaccine against influenza H5N1, we inserted three repeated kappa B (κB) motifs, separated by a 5-bp nucleotide spacer, upstream of the cytomegalovirus promoter and downstream of the SV40 late polyadenylation signal. The κB motif is a specific DNA element (10pb-long) recognized by one of the most important transcription factors NFκB. NFκB is present in almost all animal cell types and upon cell stimulation under a variety of pathogenic conditions. NFκB is released from IκB and translocates to the nucleus and binds to κB sites, ...
DNA vaccines promote an immune response by providing antigen-encoding DNA to the recipient, but the efficacy of such vaccines needs improving. Many approaches have considerable potential but currently induce relatively weak immune responses despite multiple high doses of DNA vaccine. Here, we asked whether targeting vaccine antigens to DCs would increase the immunity and protection that result from DNA vaccines. To determine this, we generated a DNA vaccine encoding a fusion protein comprised of the vaccine antigen and a single-chain Fv antibody (scFv) specific for the DC-restricted antigen-uptake receptor DEC205. Following vaccination of mice, the vaccine antigen was expressed selectively by DCs, which were required for the increased efficacy of MHC class I and MHC class II antigen presentation relative to a control scFv DNA vaccine. In addition, a DNA vaccine encoding an HIV gag p41-scFv DEC205 fusion protein induced 10-fold higher antibody levels and increased numbers of IFN-γ-producing CD4+ ...
Researchers at the Johns Hopkins Bloomberg School of Public Health and Emory developed a DNA vaccine proven to protect against measles, the most conclusive evidence yet that DNA vaccines may be useful in the fight against human disease.
A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species, reported researchers from the Perelman School of Medicine at the University of Pennsylvania.
Speaker: Honorary Doctor of Karolinska Institutet Margaret A. Liu Host: Francesca Chiodi Dr Margaret A. Liu has been appointed Honorary Doctor of Karolinska Institutet; she is honored for her frontline research and education within the field of DNA-based vaccines. Margaret Liu is the President of the International Society of Vaccines, the founder of ProTherImmune and she is affiliated with University of California, San Francisco, and Karolinska Institutet
Straus compared dl5-29 with a glycoprotein vaccine previously tested in humans and a third vaccine comprising a naked circular strand of DNA encoding the glycoprotein. Naked DNA vaccines have generated interest in recent years for their potential to elicit a stronger cellular immune response than by simply injecting the protein. Straus said that he tested dl5-29 against the best tested standard vaccine plus the competing new concept in the field, DNA vaccines, in order to get a better sense of how well the dl 5-29 vaccine performed. His team tested the vaccines both in mice and in guinea pigs. The latter is the best model of human HSV-2 disease because it is the only one that mimics many of the aspects of the human disease, such as a recurring infection interspersed with periods of latency. The researchers studied how well the vaccines worked prophylactically-to prevent infection-and therapeutically to help control an existing infection ...
The COVID-19 pandemic is accelerating development and clinical evaluation of plasmid DNA vaccines and other nucleic-acid-based therapies.
Health,Swedish researchers have expressed hope regarding the DNA vaccine tria...DNA vaccines represent the latest innovation in the area of vaccin...The technology is highly promising for producing simple inexpens...Although the study is not yet over the researchers are very posit...The second phase trial targeted at testing the effectiveness of t...,DNA,Vaccine,Trials,Against,HIV,Virus,In,Sweden,Nurture,Hope,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Vical Incorporated (Nasdaq VICL) announced today that the company s Vaxfectin adjuvant has significantly boosted the immune response of DNA-based vaccines again
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection. For the first time, researchers have shown that a combined approach - using a common cold virus to introduce a vaccine into the body, as well as an injection of a DNA-based vaccine - results in the immune system actively protecting against HIV in the gut and bodily cavities.
Our data demonstrate that a single dose of a DNA vaccine or a purified inactivated virus vaccine provides complete protection against the ZIKV challenge in mice, said senior author Dan H. Barouch, MD, PhD, Director of the Center for Virology and Vaccine Research at BIDMC, Professor of Medicine at Harvard Medical School, and Steering Committee member at the Ragon Institute of MGH, MIT and Harvard. Importantly, we showed that vaccine-induced antibodies provided protection, similar to existing vaccines for other flaviviruses. The researchers tested two vaccine candidates: a DNA vaccine developed in the Barouch laboratory at BIDMC, and a purified inactivated virus vaccine developed at WRAIR. The DNA vaccine used gene sequences from a ZIKV strain from Brazil to elicit immune responses. Four weeks following vaccination, mice were exposed to the Brazilian strain of ZIKV, which had previously been shown to cause defects in fetal mice similar to those observed in ZIKV infected humans. All vaccinated ...
A research paper has been published on the three potential Zika virus vaccines that are being tested in humans at present. Two are based on cutting-edge DNA vaccine technology and the third is based on the more standard inactivated virus model.. The DNA vaccines under development interfere with the virus ability to enter cells and replicate itself, while the inactivated vaccine aims to create an immune response that would provide future protection against Zika.. Of the three, a DNA vaccine developed by the US National Institutes of Health has progressed the furthest, with a large multi-site phase 2 trial underway involving almost 2500 test subject.. Stephen Thomas, one of the authors of the paper, said research and development has been incredibly brisk and that some groundbreaking strides have been made in very short periods of time.. The paper states: The development of a safe and effective vaccine is an urgent global health priority. Promising data from preclinical vaccine studies in ...
STONY BROOK, N.Y., & ROME - April 2, 2020 - Applied DNA Sciences Inc. - a specialist in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology - and Takis Biotech, a company focused on the development of cancer vaccines and founded by scientists from Merck Research Laboratories, today announce an expansion of their COVID-19 vaccine development program to include a fifth vaccine candidate. Production of all vaccine candidates is expected to be completed this month at Applied DNAs LinearDNA™ production facility in Stony Brook, N.Y. All vaccine candidates have also been approved by Italys Ministry of Health for preclinical animal testing that is scheduled to begin in late April 2020.. The newly added 5th linear DNA vaccine candidate encodes an engineered fusion protein of a COVID-19 Spike domain with an immunomodulator moiety, indicated ...
The attenuated live M. bovis Bacille-Calmette-Guérin (BCG) is still the sole vaccine used against tuberculosis, but confers only variable efficacy against adult pulmonary tuberculosis (TB). Though no clear explanation for this limited efficacy has been given, different hypotheses have been advanced, such as the waning of memory T-cell responses, a reduced antigenic repertoire and the inability to induce effective CD8+ T-cell responses, which are known to be essential for latent tuberculosis control. In this study, a new BCG-based vaccination protocol was studied, in which BCG was formulated in combination with a plasmid DNA vaccine. As BCG is routinely administered to neonates, we have evaluated a more realistic approach of a simultaneous intradermal coadministration of BCG with pDNA encoding the prototype antigen, PPE44. Strongly increased T- and B-cell responses were observed with this protocol in C57BL/6 mice when compared to the administration of only BCG or in combination with an empty pDNA
Inovio Pharmaceuticals is developing VGX 3100, a SynCon® therapeutic DNA vaccine for the treatment of high-grade HPV-caused pre-cancers and other related
Inovio Pharmaceuticals, Inc. announced that it has achieved compelling immune responses in a study of its multi-subtype DNA vaccine for foot-and-mouth (FMD) disease administered by its proprietary vaccine delivery technology in sheep, the second large animal in which this vaccine was evaluated. Strong protective neutralizing antibodies were also observed in pigs vaccinated with the same vaccine.
In an effort to make affordable vaccines suitable for the regions most affected by HIV-1, we have constructed stable vaccines that express an HIV-1 subtype C mosaic Gag immunogen (BCG-GagM, MVA-GagM and DNA-GagM). Mosaic immunogens have been designed to address the tremendous diversity of this virus. Here we have shown that GagM buds from cells infected and transfected with MVA-GagM and DNA-GagM respectively and forms virus-like particles. Previously we showed that a BCG-GagM prime MVA-GagM boost generated strong cellular immune responses in mice. In this study immune responses to the DNA-GagM and MVA-GagM vaccines were evaluated in homologous and heterologous prime-boost vaccinations. The DNA homologous prime boost vaccination elicited predominantly CD8+ T cells while the homologous MVA vaccination induced predominantly CD4+ T cells. A heterologous DNA-GagM prime MVA-GagM boost induced strong, more balanced Gag CD8+ and CD4+ T cell responses and that were predominantly of an effector memory ...
One of the major challenges for the development of an HIV vaccine is to induce potent virus-specific immune responses at the mucosal surfaces where transmission of virus occurs. Intranasal delivery of classical vaccines has been shown to induce good mucosal antibody responses, but so far for genetic vaccines the success has been limited. This study shows that young individuals are sensitive to nasal immunization with a genetic vaccine delivered in a formulation of a lipid adjuvant, the Eurocine N3. Intranasal delivery of a multiclade/multigene HIV-1 genetic vaccine gave rise to vaginal and rectal IgA responses as well as systemic humoral and cellular responses. As electroporation might become the preferred means of delivering genetic vaccines for systemic HIV immunity, nasal delivery by droplet formulation in a lipid adjuvant might become a means of priming or boosting the mucosal immunity. © 2008 Elsevier Ltd. All rights reserved.. ...
DNA vaccines or proteins are capable of inducing specific immunity; however, the translation to the clinic has generally been problematic, primarily due to the reduced magnitude of immune response and poor pharmacokinetics. Herein we demonstrate a composite microsphere formulation, composed of mesoporous silica spheres (MPS) and poly(d,l-lactide-co-glycolide) (PLGA), enables the controlled delivery of a prime-boost vaccine via the encapsulation of plasmid DNA (pDNA) and protein in different compartments. Method with modified dual-concentric-feeding needles attached to a 40 kHz ultrasonic atomizer was studied. These needles focus the flow of two different solutions, which passed through the ultrasonic atomizer. The process synthesis parameters, which are important to the scale-up of composite microspheres, were also studied. These parameters include polymer concentration, feed flowrate, and volumetric ratio of polymer and pDNA-PEI/MPS-BSA. This fabrication technique produced composite ...
ObjectiveTo develop a DNA cancer vaccine that targets the vascular endothelial growth factor receptor.DesignMice were vaccinated intramuscularly with listerioly
Interest in vaccine development has been rekindled over recent years due to the failure to treat infections caused by multiresistant bacteria. New technological developments such as immunoproteomics provide the platform for identifying appropriate immunogenic proteins for new vaccine design. Recombinant technology has enabled researchers to develop molecular vaccines which have been shown to elicit both cellular and humoral responses (7, 20).. We have shown that both OmpA and OmpK36 are strongly immunogenic (17), and in this investigation, the gene encoding each of the antigens was cloned in a eukaryotic plasmid which was administered as a DNA vaccine. Our results confirmed that recombinant pVAX1 plasmids containing either the ompA or the ompK36 gene were able to express the respective protein in the mammalian cells. OmpA and OmpK36 antibodies were detected in the sera of animals vaccinated with the pOmpA or the pOmpK36 plasmids.. The IgG subclass of antibodies produced against the DNA vaccine ...
Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide exclusive license and collaboration agreement with Bavarian Nordic to leverage their MVA-BN technology with Janssen s own AdVac and DNA-based vaccine technologies in the development and commercialization of potential new vaccine regimens against hepatitis B virus (HBV) and the human immunodeficiency virus (HIV-1). This agreement stems from...
Toxoplasma gondii is a widely prevalent intracellular parasite which infects almost all warm-blooded animals including humans and causes serious zoonotic toxoplasmosis. DNA vaccines have proved effective in the protection against parasites. However, the problems of weak immunity and inefficient delivery of DNA vaccine remain major issues. Therefore, comprehensive antigens derived from all stages of the parasite, effective adjuvants and delivery systems should be considered in the vaccine construction. SAG3101-144,ROP18347-396, MIC6288-347, GRA7182-224, MAG158-125, BAG1156-211 andSPA142-200, derived from antigens in tachyzoite, bradyzoite and sporozoite stages of T. gondii were screened based on CD8+ T cell epitope binding affinity to HLA and H-2. We constructed a recombinant DNA vaccine and an adenovirus vaccine encoding multi-stage antigen of T. gondii linked to ubiquitin molecules and vaccinated BALB/cmice with different strategies. Antibodies, cytokines, splenocytes
Vaccines have classically been used for disease prevention. Modern clinical vaccines are continuously being developed for both traditional use as well as for new applications. Typically thought of in terms of infectious disease control, vaccination approaches can alternatively be adapted as a cancer therapy. Vaccines targeting cancer antigens can be used to induce anti-tumour immunity and have demonstrated therapeutic efficacy both pre-clinically and clinically. Various approaches now exist and further establish the tremendous potential and adaptability of anti-cancer vaccination. Classical strategies include ex vivo-loaded immune cells, RNA- or DNA-based vaccines and tumour cell lysates. Recent oncolytic virus development has resulted in a surge of novel viruses engineered to induce powerful tumour-specific immune responses. In addition to their use as cancer vaccines, oncolytic viruses have the added benefit of being directly cytolytic to cancer cells and thus promote antigen recognition within a
Read Characterisation of IE and UL5 gene products of equine herpesvirus 1 using DNA inoculation of mice, Archives of Virology on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
Genetic vaccination using naked plasmid DNA is an immunization strategy both against infectious diseases and cancer. In order to improve the efficacy of DNA vaccines, particularly in large animals and humans, different strategies have been pursued. These vaccination strategies are based on different application routes, schedules, and coexpression of immunomodulatory molecules as adjuvants. Our mouse tumor model offers the possibility to investigate Her2/neu DNA vaccines in different settings, i.e., intramuscular or intradermal application with or without coexpression of adjuvants. Protection from tumor growth in tumor challenge experiments and both T cell and humoral immune responses against Her2/neu peptides are used as surrogate parameters for vaccine efficacy.. ...
...BLUE BELL Pa. March 14 2011 /- Inovio Pharmaceuticals...In a Phase I clinical trial of ChronVac-C using Inovios MedPulser ...This Phase II follow-on trial is an open-label single-dose randomize...,Inovio,Pharmaceuticals,Partner,ChronTech,Initiates,Phase,II,Clinical,Trial,of,Hepatitis,C,Virus,DNA,Vaccine,Using,Inovios,Electroporation,Delivery,Technology,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Our data demonstrate that a single dose of a DNA vaccine or a purified inactivated virus vaccine provides complete protection against the ZIKV challenge in mice, said senior author Dan H. Barouch, adding Importantly, we showed that vaccine-induced antibodies provided protection, similar to existing vaccines for other flaviviruses.. The researchers tested two vaccine candidates: a DNA vaccine developed in the Barouch laboratory at BIDMC, and a purified inactivated virus vaccine developed at WRAIR. The DNA vaccine used gene sequences from a ZIKV strain from Brazil to elicit immune responses.. Four weeks following vaccination, mice were exposed to the Brazilian strain of ZIKV, which had previously been shown to cause defects in fetal mice similar to those observed in ZIKV infected humans. All vaccinated mice were protected from ZIKV replication. Other mice were vaccinated and exposed to infection eight weeks later and were also protected from infection.. Barouch noted that the effectiveness of ...
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Vical or others will continue development of the Ebola vaccine; whether Vical or others will evaluate potential additional applications of the companys technology; whether the Ebola vaccine or any other product candidates will be shown to be safe and effective; whether the companys processes will result in rapid development and manufacturing of vaccines; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether the Animal Rule will be applicable to DNA-based products and whether it will provide a favorable regulatory pathway; whether Vical or its collaborative partners will succeed in marketing any product candidates; whether any funding under Project BioShield will be directed to the Ebola DNA vaccine; and ...
The DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the he
Wijesundara, D & RANASINGHE, C 2012, Prime boost regimens for enhancing immunity: magnitude, quality of mucosal and systemic gene vaccines, in J Thalhamer, R Weiss, S Scheiblhofer (ed.), Gene Vaccines, Landes Bioscience/Springer Science+Business Media, New York, pp. 183-204. ...
臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。. To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of NTU Repository with Academic Hub to form NTU Scholars.. ...
Diane Griffin, M.D., Ph.D., of Johns Hopkins University Bloomberg School of Public Health will be presenting findings on Thursday, May 31 at the 10th Annual American Society of Gene Therapy meeting in Seattle showing that an experimental measles DNA vaccine showed promising results in infant monkeys and achieved
Thermostable Vaccine Formulations: to make vaccine deployment free of the cold-chain Three types of adjuvant are being investigated: Signalling, Structural and Cellular Trafficking.. Why not download the full presentation and discover more about new generation vectored vaccines - Pushing innovation beyond the antigen to meet the health needs of resource-poor settings. · Genetic adjuvants: (i) pro-inflammatory activators (ii) multimerisation of the antigen (iii) modulators of antigen processing · Thermostable formulations for vaccines · How to translate clinical efficacy to field effectiveness Download the full presentation here ,. For more information about this and other topics discussed at the World Vaccine Congress Lyon, subscribe to the Vaccine Nation newsletter, or visit the event website. For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation. ...
For licensing purposes, besides the immunogenic aspects, deoxyribonucleic acid (DNA) vaccines present safety considerations that must be critically assessed during preclinical or/and clinical safety studies. The major concerns with regard to safety are integration of the plasmid DNA into the host ge …
Jon Rappoport, No More Fake News As my readers know, Ive been reporting on new types of technology that could be used in a coming COVID-19 vaccine-and warning about the consequences. One such technology is: DNA vaccines. They would alter recipients genetic makeup permanently. But Reuters has seen fit to claim:
Taking a two-month-old in for vaccination shots and watching them get stuck with six needles in rapid succession can be painful for child and parent alike. If the work of an MIT team of researchers pans out, those needles may be thing of the past thanks to a new dissolvable polymer film that allows ...
Immunization with DNA-based allergen vaccines has yielded promising results as a potentially novel modality of immunotherapy. Limitations to this approach include reduced immunologic responses in humans and relatively high concentrations of DNA vaccine required to induce immunity. Investigators examined the effectiveness of using a self-replicating (replicon) DNA vaccine to induce protection against allergenic sensitization in a mouse model. Mice were immunized intradermally with replicon Phl p5 DNA or conventional DNA vaccines followed by sensitization and intranasal challenge with Phl p5. Titers of IgG1, IgG2a and IgE were measured from sera, while eosinophil counts and cytokine levels were measured from BAL fluid. Lung sections were analyzed for presence of inflammatory infiltrates, increased mucus production and epithelial damage. Replicon DNA vaccination with Phl p5 resulted in reduced expression of specific IgE, Th1-biased cytokine expression, fewer eosinophils and reduced markers of ...
Dr. Gerald Zons latest Zone in with Zon blog post, dated December 2, 2013, and published by TriLink BioTechnologies of San Diego, provides a fascinating discussion of the developing use of modified mRNAs in a wide variety of key applications, including gene therapy, nucleic acid vaccines, and cellular reprogramming, as well as the possibly tremendous commercial potential of modified mRNA technology in these and other areas. Dr. Zon begins by discussing the intellectual simplicity of gene therapy, i.e., to simply replace a broken gene with the DNA of the normal gene and thus ultimately generate the normal version of the missing or altered protein. Unfortunately, it has proven remarkably difficult over three decades of work to achieve this effectively and safely. Dr. Zon attributes this in part to the challenges for cell- or tissue-specific delivery, as well as concern for adverse events generally ascribed to unintended vector integration leading to neoplasias. Nevertheless, there are presently ...
Both humoral and cellular immune responses are critical for the control of HIV infection and replication. We have established systems for production of HIV and SIV virus-like particles containing high levels of viral Env proteins using the baculovirus expression system. Evaluation of immunogenicity showed that immunization with virus-like particles induced both cellular and neutralizing antibody responses. Furthermore, mucosal administration of virus-like particles effectively induced both mucosal and systemic immune responses. These results indicate that virus-like particles consisting of HIV structural proteins are an attractive vaccine platform for eliciting anti-viral immune responses, especially neutralizing antibody responses. We have also synthesized codon-optimized genes for HIV Env proteins and evaluated their immunogenicity. Combinations of virus-like particle and DNA-based vaccination are promising for inducing strong cellular and neutralizing antibody responses against HIV ...
RANASINGHE, C & Ramshaw, I 2009, Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity, Expert Review of Vaccines, vol. 8, no. 9, pp. 1171-1181. ...
(CIDRAP News) Federal officials have announced the launch of the first clinical trial of an H5N1 avian influenza vaccine made from a piece of the viruss DNA rather than from the whole virus, an approach that may facilitate faster vaccine production.
Vaccine TechnologiesMedigen is a pioneer of novel vaccine technologies that provide inherent biological safety and unsurpassed efficacy to our vaccines. Medigens platform vaccine technologies are represented by engineered live vaccines, recombinant virus
Our Patented DNA ministrings are the safest and most efficacious DNA vectors for nonviral gene delivery. Their topology as linear covalently closed (stable) strings makes them the safest tools for therapeutic DNA delivery or genomic manipulation to date.. We designed the production platform this way from inception, and we have tested and published these outcomes in Nature affiliate journals. DNA ministrings are made through a simple shift in temperature in bacteria which makes them scalable and inexpensive to produce versus competitors that fall dramatically short in terms of production efficiency. Our current application targets colorectal (CRC) as proof of principle. Future targets include prostate cancer, intractable disease and monogenic disorders such as cystic fibrosis ...
When we have outbreaks like Ebola or Zika, there are scientists in research labs working day in and day out to find answers, treatments, or vaccines to protect us. Now, a Hattiesburg High School gr...
SAN DIEGO, Oct. 3, 2013-- Vical Incorporated today announced the publication of a new article 1 in a special DNA vaccine issue of the journal Vaccines detailing the development process from initial product concept to Phase 3 trial initiation for ASP0113, Vicals investigational therapeutic vaccine designed to control cytomegalovirus in transplant recipients.
Ive been at this blogging thing for well over 12 years now. I know, I know. Sometimes it amazes even me that I been doing this so long. I also know that Ive been mentioning just how long Ive been blogging more frequently. Sometimes I worry that the blog will turn into nothing more than posts counting down the days since I started this whole crazy thing. Of course, the main reason I mention this is not so much out of a desire for repetition but as a way of expressing amazement when I find something new and/for bizarre that I dont recall having heard before. So it was when I came across an ...
A parent who wished to make an informed decision on vaccinating their child and the difficulty they incurred at not being told the complete story.
Gorbunova and her team were able to make their observations by working with genetically-modified mice whose cells produce green fluorescent protein (GFP) that glows each time the breaks are repaired. By tracking how many cells glowed green in different tissues, the researchers determined the efficiency of repair.. We showed two things with these genetically-modified mice, said Gorbunova. Not only did the efficiency of DNA repair decline with age, but the mice began using a sloppier repair mechanism, leading to more mutations, particularly in the heart and lungs.. DNA breaks occur frequently because animal cells are under constant assault from routine activities in the environment-whether by a blast of X-rays from a visit to the doctor or simply breathing in oxygen-and, as a result, the DNA molecules often get damaged.. Using the genetically modified mice, the research team can now look at how diet, medicines, and different genetic factors also affect DNA repair in mice.. These mice may very ...
Creative Biolabs provides Mouse Anti-MS4A1 DNA-encoded mAb (Clone CBXC-2630), pVAX1 product for Biopharmaceutical research,preclinical and clinical trials.
Creative Biolabs provides Mouse Anti-MS4A1 DNA-encoded mAb (CBFYC-2970), pVAX1 product for Biopharmaceutical research,preclinical and clinical trials.
Powered by Pure, Scopus & Elsevier Fingerprint Engine™ © 2020 Elsevier B.V. We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies. Log in to Pure. ...
"The Use of Conventional Immunologic Adjuvants in DNA Vaccine Preparations". In Lowrie DB, Whalen RG (eds.). DNA Vaccines: ... Vaxjo: Comprehensive vaccine adjuvant database.. References[edit]. *^ "Guideline on Adjuvants in Vaccines for Human Use" (PDF) ... It has been speculated that the dying cells release DNA which serves as an immune alarm. Some studies found that DNA from dying ... Baylor NW, Egan W, Richman P (May 2002). "Aluminum salts in vaccines--US perspective". Vaccine. 20 Suppl 3 (Suppl 3): S18-23. ...
DNA vaccines have entered clinical trials.[49] Marburgviruses are highly infectious, but not very contagious. Importantly, and ... There are currently no Food and Drug Administration-approved vaccines for the prevention of MVD. Many candidate vaccines have ... the most promising ones are DNA vaccines[47] or based on Venezuelan equine encephalitis virus replicons,[43] vesicular ... "Marburg virus vaccines: Comparing classical and new approaches". Vaccine. 20 (3-4): 586-593. doi:10.1016/S0264-410X(01)00353-X ...
"Immunotherapy of Trypanosoma cruzi Infection with DNA Vaccines in Mice". Infect Immun. 72 (1): 46-53. doi:10.1128/IAI.72.1.46- ... the potential of DNA vaccines for immunotherapy of acute and chronic Chagas disease is being tested by several research groups. ... Megazol in a study seems more active against Chagas than benznidazole but has not been studied in humans.[76] A Chagas vaccine ... There is currently no vaccine against Chagas disease.[29] Prevention is generally focused on decreasing the numbers of the ...
... that DNA vaccines are dangerous; and that the British government have a hidden agenda. At the end of the rally, Corbyn was ... "Vaccines are safe path to freedom." The leaflet includes the false claim "some vaccines contain nanochips which can ... Anti-lockdown, anti-vaccine and anti-mask protesters crowd London's Trafalgar Square. The Independent. Coronavirus protests: ... Harpin, Lee (16 December 2020). "Piers Corbyn circulates leaflets in north London comparing vaccine campaign to Shoah". The ...
Codon optimization has applications in designing synthetic genes and DNA vaccines. Several software packages are available ... Codon usage bias refers to differences in the frequency of occurrence of synonymous codons in coding DNA. A codon is a series ... Fox JM, Erill I (June 2010). "Relative codon adaptation: a generic codon bias index for prediction of gene expression". DNA Res ... Codon usage in noncoding DNA regions can therefore play a major role in RNA secondary structure and downstream protein ...
"Preparation of pharmaceutical-grade plasmid DNA using methacrylate monolithic columns". Vaccine. 28 (8): 2039-2045. doi:10.1016 ... Improvement of Rabies Vaccine Production Using Monolithic Chromatographic Support[permanent dead link] Gutiérrez-Aguirre, Ion; ... Gagnon, Pete; Hensel, Frank; Lee, Soon; Zaidi, Simin (2011). "Chromatographic behavior of IgM:DNA complexes". Journal of ... plasmid DNA and viruses with their activity intact. Components to be separated are conveyed to the active groups located on the ...
Many candidate vaccines have been developed and tested in various animal models. Of those, the most promising ones are DNA ... DNA vaccines have entered clinical trials. Marburgviruses are highly infectious, but not very contagious. They do not get ... "Comparison of individual and combination DNA vaccines for B. Anthracis, Ebola virus, Marburg virus and Venezuelan equine ... Due to the absence of an approved vaccine, prevention of MVD therefore relies predominantly on quarantine of confirmed or high ...
She is a founder of the field of DNA-based vaccines, and studies both plasmid DNA and mRNA vaccine technologies. She was the ... She pioneered the development of DNA vaccines, which may offer "the hope of better, more stable vaccines that can be rapidly ... Liu, M. A. (24 April 2019). "A Comparison of Plasmid DNA and mRNA as Vaccine Technologies". Vaccines. 7 (2): 37. doi:10.3390/ ... Discover Magazine's 50 most important women in science RNA vaccine DNA vaccine "Margaret LIU - Dirigeant de la société Ipsen". ...
Nirenberg, Edward (24 November 2020). "No, Really, mRNA Vaccines Are Not Going To Affect Your DNA". Vaccines, Immunology, COVID ... Thus, mRNA vaccines cannot alter DNA because they cannot enter the nucleus, and because they have no primer to activate reverse ... The DNA alteration conspiracy theory was cited by a Wisconsin hospital pharmacist who deliberately removed 57 vaccine vials ... Carmichael F, Goodman J (2 December 2020). "Vaccine rumours debunked: Microchips, 'altered DNA' and more" (Reality Check). BBC ...
An important field of application are mRNA vaccines, of which the first authorized for use in humans were COVID-19 vaccines to ... Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002). From DNA to RNA (4 ed.). Garland Science. Pardi N, Weissman ... Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg AP (January 2014). "Nanoparticle vaccines". Vaccine. 32 (3): 327- ... An important application is the development of mRNA vaccines, of which the first authorized were COVID-19 vaccines (such as ...
UMMS scientists[who?] also pioneered the fundamental elements of DNA-based flu vaccines during the 1990s. UMMS Professor of ... leader of the UMMS DNA vaccine efforts, and his colleagues have partnered with PowerMed (a British immunotherapeutics company) ... vaccine, providing a substantial proportion of the U.S. requirement for this vaccine. MassBiologics participates in the ... It has introduced into general use vaccines[which?] to prevent typhus, smallpox, pertussis, tetanus, diphtheria and other ...
Gali, Weinreb (May 14, 2015). "Pfizer to collaborate on Bar-Ilan DNA robots". Globes. "Pfizer Buys Two GSK Meningitis Vaccines ... An independent panel voted 17-4 in support of the FDA approving the vaccine. On the same day, Saudi Arabia approved the vaccine ... "Covid vaccine: First 'milestone' vaccine offers 90% protection". BBC News. November 9, 2020. Kounang, Nadia (November 9, 2020 ... a meningococcal vaccine, which had $221 million in 2020 revenues; FSME/IMMUN-TicoVac, a tick-borne encephalitis vaccine, which ...
... he concentrated on the development of DNA vaccines and the details of the work has since been published as an article, DNA ... Kaushik Bharati, Sudhanshu Vrati (2013). "DNA vaccines: Getting closer to becoming a reality". Indian J Med Res. 137 (6): 1027- ... "Dna encoding ovine adenovirus (oav287) and its use as a viral vector". Google Patents. 12 December 2017. Retrieved 12 December ... "Viral Vaccines in India: An Overview". Proceedings of the National Academy of Sciences, India Section B: Biological Sciences. ...
American medical researchers develop a painless polymer skin patch that can be used to inject DNA vaccines without a ... The DNA is from a 400,000-year-old hominin femur bone fossil uncovered in Spain and matches the DNA of extinct human Denisovans ... "New painless patch may make DNA vaccines feasible". 28 January 2013. Retrieved 29 January 2013. Finley, Klint (28 ... on a single strand of synthetic DNA. DNA has immense potential as a storage medium, and may become commercially available for ...
Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. Vaccine. 2015 May 11;33(20):2347- ... Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. N Engl J Med. 2013 Nov 28;369(22):2083-92. • Johnston C, Zhu J, Jing L, ... Corey has been a central figure in the field of HIV vaccine development. The HIV Vaccine Trials Network (HVTN) now includes ... "An HIV vaccine: the world's best long-term hope for ending AIDS". "Fred Hutch featured in HBO documentary on ...
Ancient DNA evidenceEdit. DNA evidence indicates Y. pestis infected humans 5,000 years ago in Bronze Age Eurasia,[47] but ... Main article: Plague vaccine. A formalin-inactivated vaccine once was available in the United States for adults at high risk of ... "Vaccines for preventing plague". Cochrane Database Syst Rev (2): CD000976. doi:10.1002/14651858.CD000976. PMID 10796565.. ... 2013). "Yersinia pestis DNA from skeletal remains from the 6th century AD reveals insights into Justinianic Plague". PLoS ...
"Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments". PLOS ONE. 13 (1): e0188453. ... "Vaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox Virus". ... Tonix's TNX-801 is a horsepox-based live virus vaccine being developed as a potential vaccine to prevent smallpox and monkeypox ... This research collaboration will focus on developing a vaccine candidate utilizing a novel live virus vaccine vector platform ...
Morrison, Chris (1 August 2016). "DNA vaccines against Zika virus speed into clinical trials". Nature Reviews Drug Discovery. ... As of 2016 there was no available vaccine. Development was a priority of the US National Institutes of Health (NIH), but ... There is no effective vaccine. Health officials recommended that women in areas affected by the 2015-16 Zika outbreak consider ... Serological cross-reactions with closely related flaviviruses such as dengue and West Nile virus as well as vaccines to ...
... is diagnosed through a DNA probe or chemical and serological testings. No vaccine directly cures Pacheco's ... In this instance, the vaccine failed to serve its purpose as the vaccine only protected the birds against 1 serotype, rather ... This vaccine was used to stop the rapid spread of the virus and helped maintain morbidity and mortality rates in psittacine ... The detection of the virus through the DNA probe also helps identify a contaminated environment the bird has recently been ...
Integration of viral DNA[edit]. DNA oncoviruses transform infected cells by integrating their DNA into the host cell's genome.[ ... The hepatitis B vaccine is the first vaccine that has been established to prevent cancer (hepatocellular carcinoma) by ... DNA virus. HBV (B). RNA virus. CBV. HAV (A). HCV (C). HDV (D). HEV (E). HGV (G). ... forming an archetype for DNA oncoviruses. All three of these DNA oncoviruses are able to integrate their DNA into the host cell ...
"Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments". PLOS ONE. 13 (1): e0188453. ... the need for development of a new generation smallpox vaccine". Vaccine. 29 Suppl 4: D49-53. doi:10.1016/j.vaccine.2011.05.037 ... The vaccine is given using a bifurcated (two-pronged) needle that is dipped into the vaccine solution. The needle is used to ... doi:10.1016/j.vaccine.2011.02.081. PMID 21376120.. *^ "Century-old smallpox scabs in N.M. envelope". USA Today: Health and ...
Vaccine. 26 Suppl 10 (Supplement 10): K1-16. doi:10.1016/j.vaccine.2008.05.064. PMID 18847553. 18847553. Monnier-Benoit S, ... Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Prétet JL (March 2006). "Dynamics of HPV16 DNA load reflect the natural history ... It is important to note that these vaccines do not protect against 100% of types of HPV known to cause cancer. Therefore, ... Therapeutic vaccines are currently undergoing clinical trials. The lifetime recurrence rate of CIN is about 20%,[citation ...
"Rosalind Franklin :: DNA from the Beginning". Retrieved 18 September 2017. "Rosalind Franklin: A Crucial ... developers of the Polio vaccines); Paul Ehrlich (discovery of the Blood-brain barrier); In fields such as psychology and ... "Rosalind Franklin's contributions to the study of DNA". Archived from the original on 6 September 2006. Retrieved 18 ... DNA); Carl Djerassi (the pill); Stephen Jay Gould (Evolutionary biology); Baruch Samuel Blumberg (Hepatitis B virus); Jonas ...
This software was used to design and develop synthetic vaccines. Snapshot DNA Phenotyping Service is the name of a DNA ... Parabon NanoLabs has developed oncology therapeutics and synthetic vaccines using nanotechnology and DNA phenotyping. Together ... "How DNA and a tattoo led to charges in cold R.I. murder case". Providence Journal. Retrieved August 3, 2018. Forin, Jacey ( ... Also, we are using Family Tree DNA more and more all the time. Parabon is not able to upload directly but the agencies we work ...
DNA vaccination has also been explored. As of 2019, vaccine research has mainly been limited to small animal models, and ... "Status of vaccine research and development of vaccines for Chagas disease". Vaccine. 34 (26): 2996-3000. doi:10.1016/j.vaccine. ... There is no vaccine against Chagas disease. Several experimental vaccines have been tested in animals infected with T. cruzi ... Alternatively, T. cruzi DNA can be detected by polymerase chain reaction (PCR). In acute and congenital Chagas disease, PCR is ...
"A novel vaccine formulation consisting of dna vaccine inactivated virus". Orbit. 2017. "IISc-developed rabies vaccine cleared ... Later, they improved the vaccine performance by combining the DNA-based rabies vaccine with a controlled quantity of ... 464-. ISBN 978-81-317-3220-5. "DNA vaccines can be produced more rapidly than conventional vaccines". Pharmabiz. 3 January 2008 ... "Immune Response to DNA Combined Tissue Culture Inactivated anti-rabies Vaccine (DINARAB)". Indian Journals. 2017. "Gene ...
... s have also been used to deliver DNA vaccines. The delivery of plasmids into rat neurons through the use of a gene gun ... After the DNA-coated gold particles have been delivered to the cells, the DNA is used as a template for transcription ( ... Biolistics introduces DNA randomly into the target cells. Thus the DNA may be transformed into whatever genomes are present in ... Biolistic transformation involves the integration of a functional fragment of DNA-known as a DNA construct-into target cells. A ...
An immunization vaccine is produced for polio. The first successful ultrasound test of the heart activity. CERN is established ... Francis Crick and James Watson discover the double-helix structure of DNA. Rosalind Franklin contributed to the discovery of ... In 1955, Jonas Salk invented a polio vaccine which was given to more than seven million American students. In 1956, a solar ...
There is no effective vaccine against FIPV. DNA vaccination with plasmids encoding FIPV proteins failed to produce immunity. ... "Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus". J Gen Virol. 83 (Pt 1): 1- ...
Vaccine[edit]. Main article: Pneumococcal vaccine. Due to the importance of disease caused by S. pneumoniae, several vaccines ... The genome of S. pneumoniae is a closed, circular DNA structure that contains between 2.0 and 2.1 million base pairs depending ... "Pneumococcal vaccines WHO position paper--2012" (PDF). Wkly Epidemiol Rec. 87 (14): 129-44. Apr 6, 2012. PMID 24340399.. ... "Children to be given new vaccine". BBC News. 8 February 2006.. *^ "Pneumococcal Vaccination: Information for Health Care ...
Vaccines. Main article: Ebola vaccine. An Ebola vaccine, rVSV-ZEBOV, was approved in the United States in December 2019.[8] It ... December 1999). "Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the ... The DRC Ministry of Public Health approved the use of an experimental vaccine.[207][208][209] On 13 May 2018, WHO Director- ... "First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health ...
2009). "DNA vaccine encoding chimeric protein encompassing epitopes of human ZP3 and ZP4: immunogenicity and characterization ... negative regulation of transcription, DNA-templated. • phosphatidylinositol-mediated signaling. • single fertilization. • egg ... positive regulation of transcription, DNA-templated. • humoral immune response mediated by circulating immunoglobulin. • ...
... a genetic mismatch as small as a single DNA base pair is significant so perfect matches require knowledge of the exact DNA ... For this reason transplant patients must be re-vaccinated with childhood vaccines once they are off immunosuppressive ...
Vaccines[edit]. Tomatoes (along with potatoes, bananas and other plants) are being investigated as vehicles for delivering ... DNA Plant Technology (DNAP), Agritope and Monsanto developed tomatoes that delayed ripening by preventing the production of ... Goyal, R.; Ramachandran, R.; Goyal, P.; Sharma, V. (2007). "Edible vaccines: Current status and future". Indian Journal of ... Korean scientists are looking at using the tomato to express a vaccine against Alzheimer's disease.[42] Hilary Koprowski, who ...
Vaccines have been formulated and approved for prevention of Lyme disease in dogs. Currently, three Lyme disease vaccines are ... The examination of preserved museum specimens has found Borrelia DNA in an infected Ixodes ricinus tick from Germany that dates ... Poland GA, Jacobson RM (March 2001). "The prevention of Lyme disease with vaccine". Vaccine. 19 (17-19): 2303-8. doi:10.1016/ ... "Sole Lyme Vaccine Is Pulled Off Market". The New York Times. 28 February 2002. Archived from the original on 30 August 2010. ...
This is due to the accumulation of oxidative damage to DNA by aging and cellular metabolic activity and the shortening of ... Vaccine. 21 (11-12): 1180-1186. doi:10.1016/S0264-410X(02)00481-4. PMID 12559796. Ginaldi, L.; M.F. Loreto; M.P. Corsi; M. ... Vaccine. 18 (16): 1717-1720. doi:10.1016/S0264-410X(99)00513-7. PMID 10689155. Ito, K; A. Hirao; F. Arai; S. Matsuoka; K. ... immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine ...
Professor John Hermon-Taylor of Kings College London is developing a new vector type anti MAP vaccine which he claims is both ... "Mycobacterium paratuberculosis DNA in Crohn's disease tissue". Gut. 33 (7): 890-6. doi:10.1136/gut.33.7.890. PMC 1379400. PMID ...
Li ZY, Lu J, Zhang NZ, Chen J, Zhu XQ «Immune Responses Induced by HSP60 DNA Vaccine against Toxoplasma gondii Infection in ... de Santana Rocha D, de Sousa Moura RL, Maciel BM, Guimarães LA, et al «Detection of Toxoplasma gondii DNA in naturally infected ... Verma R, Khanna P «Development of Toxoplasma gondii vaccine: A global challenge» (en anglès). Hum Vaccin Immunother, 2013 Feb; ... Foroutan M, Zaki L, Ghaffarifar F «Recent progress in microneme-based vaccines development against Toxoplasma gondii» (en ...
A comparative study of DNA content as measured by flow cytometry and image analysis in 1864 specimens. Analytical Cellular ... Pandemic influenza preparedness : the critical role of the syringe.. Vaccine. 2006 May 29;24(22):4874-82. Epub 2006 March 20. K ...
regulation of transcription, DNA-templated. • transcription, DNA-templated. • negative regulation of nucleic acid-templated ... and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t ... "The DNA sequence of the human X chromosome". Nature. 434 (7031): 325-37. doi:10.1038/nature03440. PMC 2665286 . PMID 15772651 ...
Conjugate vaccine. *DNA vaccination. *Inactivated vaccine. *Live vector vaccine *Attenuated vaccine. *Heterologous vaccine ... Vaccines - a Biography edited by Andrew W. Artenstein ISBN 978-1-4419-1107-0[page needed] ... Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine (Report). Centers for Disease ... Main articles: Smallpox vaccine and Edward Jenner. In 1796, Edward Jenner, a doctor and scientist who had practiced variolation ...
radiology - randomized trial - rebound - receptor (immunology) - recombinant - recombinant DNA - recombinant DNA technology - ... AIDS Vaccine 200 - AIDS Vaccine Advocacy Coalition - AIDS wasting syndrome - AIDS-related cancer - AIDS-related complex (ARC ... V3 loop - vaccination - vaccine - vaccinia - vaginal candidiasis - valley fever - variable region - varicella zoster virus (VZV ... HIV vaccine trials network (HVTN) - HIV-1 - HIV-2 - HIV-associated dementia - HIV-related tuberculosis - HLA - Hodgkin's ...
This DNA can be incorporated into host genome as a provirus that can be passed on to progeny cells. The retrovirus DNA is ... and impedes the development of effective vaccines and inhibitors for the retrovirus.[9] ... It has been speculated that the RNA to DNA transcription processes used by retroviruses may have first caused DNA to be used as ... All members of Group VI use virally encoded reverse transcriptase, an RNA-dependent DNA polymerase, to produce DNA from the ...
Chaves SS, Gargiullo P, Zhang JX, et al. (2007). "Loss of vaccine-induced immunity to varicella over time". N Engl J Med 356 ( ... DNA) பரிசோதனையும் செய்யப்படலாம்.[10] ... "Chickenpox (Varicella) Vaccine". Immunization Action Coalition (October 2005). பார்த்த நாள் 2006-06-12. ...
Use in vaccinesEdit. The first vaccine against smallpox by Edward Jenner in 1800 was by infection of a zoonotic bovine virus ... but there is increasing evidence from DNA and RNA sequencing, that measles, smallpox, influenza, HIV, and diphtheria came to ...
2005). "Mitochondrial DNA and retroviral RNA analyses of archival oral polio vaccine (OPV CHAT) materials: evidence of macaque ... doi:10.1016/j.vaccine.2004.10.038. பப்மெட் 15705467. *↑ "Oral Polio Vaccine and HIV / AIDS: Questions and Answers". Centers for ... 2004). "Origin of AIDS: contaminated polio vaccine theory refuted". Nature 428 (6985): 820. doi:10.1038/428820a. பப்மெட் ... 1986). "Transactivation of the human immunodeficiency virus long terminal repeat sequences by DNA viruses". Proc. Natl. Acad. ...
Vanderbilt is also the home of BioVU, one of the world's largest DNA databanks, which holds more than 170,000 samples and is ... In the early 1940s, Ernest Goodpasture developed the method of culturing vaccines in chick embryos, which allowed the mass ... production of vaccines to prevent viral diseases worldwide.[14]. *In the 1950s, Amos U. Christie, chair of pediatrics, led a ...
Vaccines are examples of antigens in an immunogenic form, which are intentionally administered to a recipient to induce the ... For human tumors without a viral etiology, novel peptides (neo-epitopes) are created by tumor-specific DNA alterations.[15] ... An autoantigen is usually a normal protein or protein complex (and sometimes DNA or RNA) that is recognized by the immune ... the adjuvant component of vaccines plays an essential role in the activation of the innate immune system.[10][11] ...
Reynell, L; Trkola, A (2012-03-02). "HIV vaccines: an attainable goal?". Swiss medical weekly 142: w13535. PMID 22389197. doi: ... the exploitation of host DNA repair mechanisms by retroviruses". ACS Chem Biol 1 (4): 217-26. PMID 17163676. doi:10.1021/ ... Walker, BD (2007 Aug-Sep). "Elite control of HIV Infection: implications for vaccines and treatment.". Topics in HIV medicine ... "HIV Vaccine Trial in Thai Adults". Consultado o June 28, 2011 ...
South African Tuberculosis Vaccine Initiative i Aeras Global TB Vaccine Foundation.[125] Aeras Global TB Vaccine Foundation ... "Detection of Mycobacterial DNA in Andean Mummies". J Clin Microbiol. svezak 40 (broj 12): str. 4738.-4740. PMC 154635. PMID ... 119,0 119,1 119,2 Martín Montañés, C; Gicquel, B (2011). "New tuberculosis vaccines.". Enfermedades infecciosas y microbiologia ... pristupljeno 26. srpnja 2011.. *↑ "BCG Vaccine Usage in Canada -Current and Historical" ...
... these include synthetic insulin which was produced in 1979 using recombinant DNA and the first genetically engineered vaccine ... DNA sequencing, a method developed by Walter Gilbert and Frederick Sanger in 1977,[5] caused a rapid change the development of ... Most DNA viruses assemble in the nucleus while most RNA viruses develop solely in cytoplasm.[22][23] ... Once the virus has gained access to the host's cells, the virus' genetic material (RNA or DNA) must be introduced to the cell. ...
The sequencing of the influenza genome and recombinant DNA technology may accelerate the generation of new vaccine strains by ... background for pandemic influenza vaccine safety monitoring". Vaccine. 27 (15): 2114-20. doi:10.1016/j.vaccine.2009.01.125. ... "Vaccine. 26 Suppl 4: D49-53. doi:10.1016/j.vaccine.2008.07.039. PMC 3074182. PMID 19230160.. ... Research into new vaccines is particularly important, as current vaccines are very slow and expensive to produce and must be ...
Viral pathogenesis • Preventive and therapeutic vaccines. 11: 63-9. doi:10.1016/j.coviro.2015.02.002. PMC 4827424. PMID ... This enzymatic process produces one of the fundamental biopolymers found in cells (along with DNA, RNA, and proteins). ... The process is non-templated (unlike DNA transcription or protein translation); instead, the cell relies on segregating enzymes ... "Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design". Current Opinion in Virology ...
DNA-based tests[edit]. These are based on detecting a leukaemic specific DNA sequence. Generally this is achieved through the ... cancer vaccines. Areas of current research and controversies[edit]. Clinical usefulness of MRD tests[edit]. It is important ... Both the DNA and RNA based tests require that a pathologist examine the bone marrow to determine which leukaemic specific ... The DNA sequence chosen may contribute to the genesis of the leukaemia, or may simply be linked to it. ...
... so diphtheria vaccine contains one single protein; ... deoxyribonucleic acid, n. అరైకామ్లం; DNA;. *depart, v. i. ...
PCR identifies the parasite DNA but this technique is not rapid and cannot be used for routine identification. PCR is also ... Public health, Prevention strategies and Vaccines[edit]. *Mosquito bed nets. *Medication - Mefloquine, Chloroquine ...
Vaccine[edit]. As of 2017[update], no approved vaccines are available. A phase-II vaccine trial used a live, attenuated virus, ... a nonstructural protein that degrades RBP1 and turns off the host cell's ability to transcribe DNA.[51] NS2 interferes with the ... "Vaccine. 29 (16): 3067-73. doi:10.1016/j.vaccine.2011.01.076. PMC 3081687. PMID 21300099.. ... "Expert Review of Vaccines. 11 (9): 1087-101. doi:10.1586/erv.12.84. PMC 3562718. PMID 23151166.. ...
Bacteria also use DNA adenine methylation (rather than DNA cytosine methylation) as an epigenetic signal. DNA adenine ... the bacterium to randomly change its characteristics into six alternative states that could pave the way to improved vaccines. ... DNA damage can also cause epigenetic changes.[27][28][29] DNA damage is very frequent, occurring on average about 60,000 times ... Chromatin is the complex of DNA and the histone proteins with which it associates. If the way that DNA is wrapped around the ...
Vaccine hysterics tell us that the science is split on whether vaccinations cause autism. And AIDS denialists say that ... The Royal Society review (2002) concluded that the risks to human health associated with the use of specific viral DNA ... " "Crops and foods produced using recombinant DNA techniques have been available for fewer than 10 years and no long-term ...
Human trials testing DNA vaccines against influenza virus, malaria, hepatitis B virus, HIV, herpes simplex virus, colon cancer ... A DNA vaccine designed to activate the MHC I arm of the immune system may be uniquely suited to fight viral infections. ... DNA Delivery Methods -- What is Naked DNA?. *DNA Vaccine for Influenza. *How DNA Vaccines Differ from Recombinant DNA Vaccines ... DNA Delivery Methods -- What is Naked DNA?. *DNA Vaccine for Influenza. *How DNA Vaccines Differ from Recombinant DNA Vaccines ...
DNA vaccines have entered into a variety of human clinical trials for vaccines against various diseases including cancer. ... where the safety and tolerability of the DNA platform are substantiated. In this review on DNA vaccines, salient aspects on ... Evidence that DNA vaccines are well tolerated and have an excellent safety profile proved to be of advantage as many clinical ... It is clear from the results obtained in clinical trials that such DNA vaccines require much improvement in antigen expression ...
"The patch was designed with delivering DNA-based vaccines in mind. Thus far efforts to use DNA to generate more robust and safe ... Polymer Patches May Enable Effective DNA Vaccines 83 Posted by Unknown Lamer on Wednesday January 30, 2013 @10:49AM. from the ... Submission: Polymer Patches Could Replace Needles and Enable More Effective DNA Vaccines. ... This development will not only make vaccinations less harrowing, but also allow for developing and delivering vaccines for ...
The first prostate cancer vaccine could be a step away after ministers gave their approval for a human trial of a new ... Prostate cancer vaccine uses DNA to fight disease. The first prostate cancer vaccine could be a step away after ministers gave ... No vaccines have yet been approved in Britain to treat any type of cancer, and scientists believe it could not only double the ... Because the vaccine, known as Prostvac, has been genetically modified researchers had to seek approval from the Department for ...
The DNA vaccines are simple rings of DNA containing a gene encoding an antigen, and a promoter/terminator to make the gene ... The DNA vaccines are simple rings of DNA containing a gene encoding an antigen, and a promoter/terminator to make the gene ... The breadth of applications for DNA vaccines thus ranges from prophylactic vaccines to immunotherapy for infectious diseases, ... preclinical and clinical efficacy of DNA vaccines, and point out the limitations of the first generation of such vaccines, and ...
Buy DNA Vaccines by Douglas B. Lowrie, Robert Whalen from Waterstones today! Click and Collect from your local Waterstones or ... DNA Vaccines: Methods and Protocols - Methods in Molecular Medicine 29 (Hardback). Douglas B. Lowrie (editor), Robert Whalen ( ... The field of DNA vaccines has undergone explosive growth in the last few years. As usual, some historical precursors of this ... "Work on the development of DNA vaccines continues aspace for a huge range of potential applications and this book will be ...
Former pharmaceutical scientist believes that using human DNA in making viral vaccines like the MMR vaccine, may increase the ... Former pharmaceutical scientist believes that using human DNA in making viral vaccines like the MMR vaccine, may increase the ... DNA, chemicals and other ingredients are in vaccines. NVIC publishes a Vaccine E-newsletter regularly with alerts about vaccine ... Which Vaccines Might Be Produced Using Aborted Fetal Cell Lines?. Chicken pox vaccine is not the only vaccine manufactured in ...
... and the DNA vaccine. Such cooperative strategies delivering vaccine in a single, simple platform result in improved cellular ... Enhancing DNA vaccine potency remains a challenge. It is likely that APCs, and especially DCs, play a paramount role in the ... DNA vaccination is a novel immunization strategy that has great potential for the development of vaccines and immune ... Proposed schematic of chemokine-induced traffic and activation of DCs following DNA vaccination with plasmid-encoded Flt3L and ...
Human DNA was not decoded until 1983. Therefore, any vaccine produced before this time could not have included any DNA testing ... In vaccines, 100,000,000 bits and strands of human and or mammalian DNA are allowed per dose. This does not include viral ... Has anyone tested the current range of vaccines for such contaminations?. *Has anyone wondered if injecting human DNA back into ... The science community marginalizes the possibility that residual DNA could pose health risks for those injected with vaccines ...
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection. One is now being ... DNA vaccines protect monkeys against Zika virus At a Glance. *Two experimental Zika virus DNA vaccines developed by NIH ... Scientists from NIAIDs Vaccine Research Center developed 2 experimental DNA vaccines against Zika virus. The team, led by Drs ... DNA vaccines have been shown to be safe in previous clinical trials for other diseases. They dont contain infectious material ...
... and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA ... The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate ... Keywords: DNA vaccine; genetic adjuvants; electroporation DNA vaccine; genetic adjuvants; electroporation This is an open ... Vaccines 2014, 2, 89-106. AMA Style. Okuda K, Wada Y, Shimada M. Recent Developments in Preclinical DNA Vaccination. Vaccines. ...
DNA vaccines have evolved as a clinically safe and effective platform for priming HIV-specific cellular and humoral responses ... Since the initial proof-of-concept studies examining the ability of antigen-encoded plasmid DNA to serve as an immunogen, ... Vaccines. 2014; 2(1):160-178. Chicago/Turabian Style. Iyer, Smita S.; Amara, Rama R. 2014. "DNA/MVA Vaccines for HIV/AIDS." ... Vaccines 2014, 2, 160-178. AMA Style. Iyer SS, Amara RR. DNA/MVA Vaccines for HIV/AIDS. ...
... is the entry key that allows the virus into cells.With this DNA vaccine, our cells temporarily become factories producing the ... These cells recognize the DNA fragment and transcribe it into an RNA fragment capable of inducing production of the SARS-CoV-2 ... The principle is to inject a DNA fragment into human cells. ... Covid-19: a DNA vaccine. *Covid-19: vaccine against SARS-CoV-2 ... Of all the vaccines developed at the Institut Pasteur for SARS-CoV-2 (the virus that causes COVID-19), the DNA vaccine ...
The National Vaccine Information Center urges the FDA recommend the suspension of the use of RotaTeq vaccine until more is ... Were RotaTeq vaccine seed stocks contaminated with PCV1 and PCV2 DNA as well? And why does RotaTeq vaccine have allowable ... DNA fragments from a bird virus in measles vaccine by the same private lab that identified pig viral DNA in rotavirus vaccine, ... NVIC Statement on Finding of PCV DNA Sequences in Rotavirus Vaccines. Barbara Loe Fisher, Co-founder & President National ...
DNA-vaccine kaldes også DNA-baseret vaccine eller gen-baseret vaccine og er en nukleinsyre-baseret vaccine, en type vaccine, ... Engineering DNA vaccines against infectious diseases. Acta Biomaterialia 2018 *^ a b c "DNA vaccines". World Health ... DNA Immunization for HIV Vaccine Development. Vaccines 2014 *^ Vaccine innovation spurred by the long wait for an Ebola virus ... en DNA-vaccine mod coronavirus.[11][12] En DNA-vaccine mod coronavirus er udviklet af firmaet Inovio.[13] ...
Plasmid DNA Vaccines indicating they may negatively impact Infertility, Vaccination: Abortion, and Vaccine-induced Toxicity ... Diseases : Infertility, Vaccination: Abortion, Vaccine-induced Toxicity Anti Therapeutic Actions : Vaccination: Plasmid DNA ... DNA plasmid vaccines may carry under reported risks associated with structural instability.Aug 01, 2010. ... 2 Abstracts with Vaccination: Plasmid DNA Vaccines Research. Filter by Study Type. Animal Study. ...
DNA) vaccines present safety considerations that must be critically assessed during preclinical or/and clinical safety studies ... The major concerns with regard to safety are integration of the plasmid DNA into the host ge … ... DNA vaccines: safety aspect assessment and regulation Dev Biol (Basel). 2006;126:261-70; discussion 327. ... For licensing purposes, besides the immunogenic aspects, deoxyribonucleic acid (DNA) vaccines present safety considerations ...
Autism And Cancer Related To Human Fetal DNA In Vaccines. Study By Global Research News. Global Research, September 19, 2014. ... Instead of conducting safety studies they regulated the amount of human DNA that could be present in a vaccine to no greater ... "The MMR II and chickenpox vaccines and indeed all vaccines that were propagated or manufactured using the fetal cell line WI-38 ... ...
The Murine Intravaginal HSV-2 Challenge Model for Investigation of DNA Vaccines.. Marshak JO1, Dong L1, Koelle DM2,3,4,5,6. ... DNA vaccines have been licensed in veterinary medicine and have promise for humans. This format is relatively immunogenic in ... Animal model; Antibody; DNA vaccine; Dorsal root ganglia; Herpes simplex virus; Latency; Polymerase chain reaction ... Herein, we detail lessons learned investigating candidate DNA vaccines in the progesterone-primed female mouse vaginal model of ...
Pandemic Influenza Plasmid DNA Vaccines (Needle-Free). The safety and scientific validity of this study is the responsibility ... Qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine. Subjects will ... and Immunogenicity of Pandemic Influenza Plasmid DNA Vaccines Administered With the Biojector® 2000 Needle-Free System. ... No use of aspirin and/or anticoagulants within 2 weeks of the administration of the investigational vaccines ...
Submission + - Polymer Patches Could Replace Needles and Enable More Effective DNA Vaccines ( Submitted by Zothecula ... Polymer Patches Could Replace Needles and Enable More Effective DNA Vaccines. Archived Discussion. Load All Comments ... Polymer Patches Could Replace Needles and Enable More Effective DNA Vaccines More Login ... This development will not only make vaccinations less harrowing, but also allow for developing and delivering vaccines for ...
... Yongping Jiang, Hongbo Zhang, Guojun Wang, Pingjing Zhang, ... "Protective Efficacy of H7 Subtype Avian Influenza DNA Vaccine," Avian Diseases Digest, 5(s1), (1 March 2010) Include:. ... "Protective Efficacy of H7 Subtype Avian Influenza DNA Vaccine," Avian Diseases Digest 5(s1), (1 March 2010). ...
DNA. by Ethan A. Huff, staff writer (NaturalNews) The National Vaccine Information Center (NVIC), a non-profit vaccine safety ... MRC-5 has admittedly been used to developed the Varivax vaccine for chicken pox, the ProQuad vaccines for both chicken pox and ... According to the manufacturer-produced package inserts included with each vaccine batch, many vaccines are made with disturbing ... and human albumin and DNA derived from other unknown sources are all being used to develop many of the vaccines being injected ...
KEY FINDINGSThe Asia-Pacific DNA vaccine market was calculated to be worth $154 million in 2016 and is predicted to generate a ... Companion Animal Vaccines (Canine Vaccines, & Feline Vaccines), and Livestock Vaccines (Porcine ... ... The Asia-Pacific DNA vaccine market was calculated to be worth $154 million in 2016 and is predicted to generate a revenue of $ ... This report analyzes the worldwide markets for Veterinary Vaccines in US$ by the following Product Segments: ...
Correlates with Aborted Fetal DNA in Vaccines Study Confirms Autism Boom - Correlates with Aborted Fetal DNA in Vaccines News ... SCPI has affirmed that they are continuing to study the impact of residual human fetal DNA in vaccines on the brain development ... "For years the evidence has pointed toward the link between vaccines using DNA from aborted babies and the rise of Autism ... Study Confirms Autism Boom - Correlates with Aborted Fetal DNA in Vaccines. Fri Apr 23, 2010 - 12:15 pm EST ...
Research on SARS-CoV-2 RNA by scientists at Harvard and MIT has implications for how mRNA vaccines could permanently alter ... genomic DNA, according to Doug Corrigan, Ph.D., a biochemist-molecular biologist who says more research is needed. ... Could mRNA vaccines permanently alter DNA? Recent science suggests they might Could mRNA vaccines permanently alter DNA? Recent ... Could mRNA vaccines permanently alter DNA? Recent science suggests they might. Research on SARS-CoV-2 RNA by scientists at ...
In contrast to the full-length env DNA vaccine, vaccination of macaques with a combination of these 2 Env CE DNA induced robust ... boosting of the Env CE DNA primed macaques with the intact env DNA vaccine potently augmented pre-existing immunity, increasing ... HIV Env conserved element DNA vaccine alters immunodominance in macaques.. Hu X1, Valentin A2, Rosati M2, Manocheewa S3, Alicea ... Env CE DNA vaccine induces T cell responses in macaques. (A) Cartoon shows the vaccination regimen used to prime of macaques. ...
A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimers disease, ... 20, 2018 - A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimers ... The research published in Alzheimers Research and Therapy demonstrates how a vaccine containing DNA coding for a segment of ... DNA vaccine reduces both toxic proteins linked to Alzheimers. UT Southwestern Medical Center ...
DNA plasmid-based vaccine, genomic DNA, salmon, study design, DNA integration, genetically modified organisms, Directive 2001/ ... As protection against pancreas disease, Novartis developed a prophylactic DNA plasmid-based vaccine to be administered to ... data for the assessment of DNA integration into the fish genome of a genetically modified DNA plasmid-based veterinary vaccine ... presented by Novartis Animal Health on the integration/non-integration of DNA plasmid-based vaccine into the salmon genomic DNA ...
... Erdal Eroglu,1,2 Ankur Singh,3 Swapnil Bawage,1 Pooja M. Tiwari,4 Komal Vig ... "Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus," Vaccine, ... "Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles," Vaccine, vol. 22, no. ... S. Gurunathan, C.-Y. Wu, B. L. Freidag, and R. A. Seder, "DNA vaccines: a key for inducing long-term cellular immunity," ...
  • The MHC I pathway is used predominantly for immune presentation of endogenously synthesized proteins such as would occur following DNA immunization. (
  • This is a book that should be in everyone's library who is interested in pursing studies employing DNA immunization and for graduate students interested in an up-to-date understanding of DNA vaccination. (
  • The National Network for Immunization Information (NNII) has an article on their website explaining the rationale for using human fetal cells, and the history of how they've been used in vaccine production. (
  • DNA vaccination is a novel immunization strategy that has great potential for the development of vaccines and immune therapeutics. (
  • The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. (
  • The group pointed out in its most recent newsletter that 1988 is the same year the U.S. Advisory Committee on Immunization Practices began recommending a second dose of the MMR vaccine, which included cells derived from the tissue of aborted babies. (
  • Several DNA-based methods of immunization (CpG DNA, CpG DNA conjugated to a protein allergen, and plasmid DNA) have shown promise in animal models of asthma, and some of these DNA-based therapies have entered phase I/II clinical trials. (
  • Here, we describe an electroporation-based immunization technique capable of administering a cocktail of DNA vaccinations in vivo. (
  • CDC (2000) Use of anthrax vaccine in the united states: recommendations of the advisory committee on immunization practices. (
  • Robinson HL, Ginsberg HS, Davis HL, Johnston SA, Liu MA (1997) The scientific future of DNA for immunization. (
  • The effectiveness of this vaccine was evaluated in preclinical studies that showed a single immunization elicited broad T and B cell immune responses in mice similar to those induced naturally in POWV-infected individuals, and that vaccine-induced immunity provided protection in a POWV challenge animal model. (
  • Results from a mouse study demonstrated that immunization with a Vaxfectin®-formulated bivalent CMV vaccine, expressing gB and pp65, resulted in durable cellular immune responses. (
  • While another DNA vaccine -generated by a team including Michael and researchers from Harvard Medical School and University of São Paulo, Brazil-is not intended for the clinic, the DNA vaccine examined in the present study and another immunization-being developed by Inovio Pharmaceuticals-could both eventually be used to protect people against Zika infection. (
  • A single immunization dose of either vaccine generated neutralizing antibodies in mice, the researchers reported. (
  • 12][13] DNA immunization is also being investigated as a means of developing antivenom sera. (
  • 14] DNA immunization can be used as a technology platform for monoclonal antibody induction. (
  • As compared with non-DC-targeting vaccines, intramuscular immunization via electroporation (EP) of the fusion DNA in mice elicited consistently high frequencies of GAG-specific, broadly reactive, polyfunctional, long-lived, and cytotoxic CD8 + T cells and robust anti-GAG antibody titers. (
  • We previously hypothesized that pressures to minimize adverse effects and maintain tuberculin reactivity during this time resulted in impotent vaccines that consistently induce tuberculin sensitivity with immunization ( 3 ). (
  • This procedure, known as a DNA vaccine, is perhaps better described as DNA-mediated or DNA based immunization, with the understanding that the objective is not to raise an immune response to the DNA itself. (
  • DNA plasmids encoding foreign proteins may be used as immunogens by direct intramuscular injection alone, or with various adjuvants and excipients, or by delivery of DNA-coated gold particles to the epidermis through biolistic immunization. (
  • Antibody, helper T lymphocyte, and cytotoxic T lymphocyte (CTL) responses have been induced in laboratory and domesticated animals by the direct inoculation of DNA plasmids encoding foreign proteins, either intramuscularly or by delivery of DNA-coated gold particles to the epidermis through biolistic immunization. (
  • In the last years, rational approaches to improve the efficacy of DNA vaccines were developed and include: modifications of plasmid basic design, use of next-generation delivery methods, addition of adjuvants in the formulation, improvement in immunization protocols and even targeting to dendritic cells. (
  • can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization? (
  • Plasmid DNA, as another method of antigen delivery, offers significant potential safety and manufacturing advantages over other immunization approaches. (
  • Our group has evaluated repetitive immunization with plasmid DNA vaccines in rodent models, and has translated this approach to early clinical trials in men with low-volume recurrent prostate cancer with a DNA vaccine encoding PAP. (
  • We determined that immunization with plasmid DNA elicited antigen-specific IFNγ-secreting T cells that led to increased expression of PD-L1 on antigen-expressing tumor cells. (
  • However, immunization with the vaccine encoding high affinity epitopes resulted in antigen-specific CD8+ T cells with higher PD-1 expression. (
  • Conversely, immunization with plasmid DNA engineered to increase the duration of antigen expression led to CD8+ T cells with normal PD-1 expression but higher LAG-3 expression. (
  • In the case of patients immunized with a DNA vaccine encoding PAP, we have recently found that PD-L1 expression on circulating tumor (CD45-EpCAM+) cells was increased following immunization, analogous to our murine studies. (
  • Finally, using a trans vivo delayed type hypersensitivity (tvDTH) assay, we observed that PAP-specific immune responses in T cells obtained from patients after immunization with a DNA vaccine encoding PAP could be "uncovered" with PD-1 blockade but not blockade with anti-LAG-3 or anti-TIM-3. (
  • Newswise - PHILADELPHIA - (April 22, 2021) - A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) developed at The Wistar Institute induced potent immune responses and afforded protective efficacy in non-human primate (NHP) models when given intradermally in abbreviated, low-dose immunization regimen. (
  • Researchers evaluated the immunogenicity and protective efficacy of their MERS synthetic vaccine when delivered intradermally using a shortened two-dose immunization schedule compared with intramuscular delivery of higher doses in NHP. (
  • Other driving factors are increasing funds from philanthropy organizations such as Bill and Melinda Gates foundation, inclusion of several new vaccines in the national immunization schedule of many countries, development of new vaccines which includes vaccine for hepatitis, growing awareness of vaccination, growth of manufacturing low cost vaccines especially in developing countries, the entry of China in the vaccine market etc. (
  • Both pcDNA3.1-S1 DNA vaccine immunization and passive transfer of immune serum from pcDNA3.1-S1 vaccinated mice protected Ad5-hDPP4-transduced mice from MERS-CoV challenge. (
  • This and other early studies, demonstrating the feasibility of direct intramuscular gene transfer for DNA vaccination purpose, propelled the first vaccination studies utilizing plasmid DNA in protection scenarios involving influenza [ 5 ] and HIV-1 [ 6 ]. (
  • Tecular Biology series, consists of 41 well written and referenced chapters dealing with certain aspects of DNA vaccination. (
  • The subjects addressed range from large scale plasmid isolation to DNA vaccination and autoimmunity, and illuminate the explosive growth this field has undergone in recent years. (
  • In short, this book is a valuable addition to the library of all people actively involved in the field of DNA vaccination. (
  • Proposed schematic of chemokine-induced traffic and activation of DCs following DNA vaccination with plasmid-encoded Flt3L and MIP-1α. (
  • Shimada, M. Recent Developments in Preclinical DNA Vaccination. (
  • Since the initial proof-of-concept studies examining the ability of antigen-encoded plasmid DNA to serve as an immunogen, DNA vaccines have evolved as a clinically safe and effective platform for priming HIV-specific cellular and humoral responses in heterologous "prime-boost" vaccination regimens. (
  • DNA-vaccine kaldes også DNA-baseret vaccine eller gen-baseret vaccine og er en nukleinsyre -baseret vaccine, en type vaccine , der i stedet for at benytte et antigen til vaccination , bruger et gen , en DNA -sekvens, der koder for antigenet. (
  • Indtil videre er der forsket og udviklet i DNA-vacciner, men så meget står klart, nemlig at vaccination med DNA giver et antal potentielle fordele i forhold til traditionelle fremgangsmåder, herunder stimulering af både B- og T-celleresponser , forbedret vaccinestabilitet, fraværet af en infektiøs sygdomsfremkaldende mikroorganisme og en relativ lethed ved fremstilling i stor skala. (
  • Som bevis på princippet om DNA-vaccination er der opnået immunrespons i dyr ved hjælp af gener fra en række sygdomsfremkaldende mikroorganismer. (
  • Alternativt til vaccination med DNA i en plasmid kan vaccination ske med DNA indbygget i en virus-vektor, som f.eks. (
  • As it turns out, there are at least eight, and as many as 23, vaccines routinely administered to children that contain one or more of these questionable ingredients -- and if the general public truly knew about this, there would likely be a massive vaccination fallout resulting in the complete collapse of the vaccine industry. (
  • PCR based analysis of genomic DNA from muscle samples, taken from at or around the injection site 436 days post vaccination, led the company to conclude that integration of plasmid DNA into the fish genome is extremely unlikely. (
  • Electroporation of DNA vaccines, whereby tissues injected with DNA are subjected to localized electrical currents, is an ideal platform technology that achieves protective immune responses to multivalent vaccination. (
  • Researchers evaluated the potential of engineered LAB to deliver nucleic acids vaccines to fish cells, providing a proof of principle that food grade lactic acid bacteria (LAB) can be used as a vehicle for the oral vaccination of fish," says project coordinator Dr Maria Forlenza. (
  • The choice of virus and antigen is based on work showing that injection vaccination with DNA plasmids encoding the G protein of SVCV is highly successful. (
  • DNA vaccination is a novel and rapidly developing approach for prevention and therapy of disease, which utilizes genetically modified plasmids with added genetic sequences that encode specific antigens and allows the body to produce them. (
  • The gene-altering vaccination would tweak human DNA into a cell line major corporations could patent, hypothetically owning the people with altered DNA. (
  • Still, Dr. Baltimore says that he envisions that some people might be leery of a vaccination strategy that means altering their own DNA, even if it prevents a potentially fatal disease. (
  • The enormous tonnage of propaganda about vaccines, and the resultant mandatory laws that enforce vaccination, create a powerful channel along which re-engineering is eminently possible. (
  • DNA vaccination, one of the latest biotechnological breakthroughs, is the beginning of a new chapter in vaccine technology. (
  • The high frequency of durable and protective GAG-specific CD8 + T cell immunity induced by soluble PD1-based vaccination suggests that PD1-based DNA vaccines could potentially be used against HIV-1 and other pathogens. (
  • This review highlights the salient features of DNA vaccines, and measures to enhance their efficacy so as to devise an effective and novel vaccination strategy against animal diseases. (
  • Porcine interleukin-3 enhances DNA vaccination against classical swine fever. (
  • A single HBsAg DNA vaccination in combination with electroporation elicits long-term antibody responses in sheep. (
  • Gene gun-mediate DNA vaccination against foot-and-mouth disease virus. (
  • Protection of cattle against bovine leukemia virus (BLV) infection could be attained by DNA vaccination. (
  • In a number of animal models, immune responses induced by DNA vaccination have been shown to be protective against challenge with various infectious agents. (
  • The Asia-Pacific region is expected exhibit the fastest growth between 2018-2026, due to emerging interests in third-generation DNA vaccination, government support, and increasing conduction of clinical trials. (
  • Today's FMD vaccines based on killed/inactivated viruses can actually cause FMD infection, so are only used regionally after an outbreak rather than for broad preemptive vaccination. (
  • Therefore, further development of the current HBV vaccines to improve the efficacy of vaccination would be desirable. (
  • Vaccination is nowadays the most efficient way of controlling infectious diseases and the search for new and improved vaccines continues as a way to ameliorate human health. (
  • Other promising trials make use of DNA vaccines against malaria and hepatitis B. The papers inform the reader about the immune basis of this form of vaccination and about approaches being developed to increase the efficacy of DNA vaccines in humans. (
  • An excellent up-to-the-minute account, this volume should be read by anyone in academia or in industry involved in DNA vaccination. (
  • DNA cancer vaccination strategies target SV40 large tumour antigen in a murine experimental metastasis model. (
  • Vaccination with DNA-SIV + ALVAC-SIV + gp120 alum results in inflammasome activation, high levels of IL-1β production, emergency myelopoiesis, and the egress of CXCR4 + CD14 + pre-monocytes from bone marrow. (
  • DNA vaccination thus induces innate immunity by engaging three subsets of myeloid cells, M-MDSCs, CD14 + innate monocyte memory, and CD16 + monocytes all playing different role in protection. (
  • Mice immunized with the PDGFRβ vaccine demonstrated a small, but statistically significant decrease in lung weight in comparison to controls, whereas both the Flk1 and the Flk1 plus PDGFRβ combination vaccination groups revealed a marked decrease in lung weight compared to controls. (
  • DNA vaccination with the MERS-CoV S1 gene markedly increased the frequencies of antigen-specific CD4+ and CD8+ T cells secreting IFN-γ and other cytokines. (
  • DNA Vaccines: Design of a Gene to Eradicate HIV offers an innovative and new strategy to combat deadly viral infections. (
  • Binding a transcription factor directly to a viral genome is intended to silence the genome, preventing transcription if embedded in the DNA or interfering with translation if the genome is present in a cell's cytoplasm as RNA. (
  • The recent identification and characterization of genes coding for tumour antigens (Ag) has enabled the design of antigen-specific cancer vaccines based on plasmid DNA and recombinant viral vectors. (
  • The year 1993 saw the publication of further improvements in the me- ods of naked DNA delivery and, above all, the first demonstrations by several groups of the induction of humoral and cytotoxic immune responses to viral antigens expressed from injected plasmid DNA. (
  • The team, led by Drs. Theodore C. Pierson and Barney S. Graham, engineered circular pieces of DNA to contain genes that code for viral proteins. (
  • The last two decades have seen significant progress in the DNA-based vaccine platform with optimized plasmid constructs, improved delivery methods, such as electroporation, the use of molecular adjuvants and novel strategies combining DNA with viral vectors and subunit proteins. (
  • And why does RotaTeq vaccine have allowable thresholds of residual monkey viral DNA? (
  • If there continues to be a dispute in the 21st century about whether monkey viruses or monkey viral DNA in vaccines can, in fact, cause cancer in humans, there is no dispute that polio vaccines were contaminated with a monkey virus. (
  • Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon," Vaccine , vol. 11, no. 14, pp. 1415-1423, 1993. (
  • DNA vaccines have been shown to be extremely effective in protecting fish against various viral diseases. (
  • The vaccine is produced by growing bacteria that have been engineered to make the viral DNA, he told CIDRAP News. (
  • The company previously reported encouraging data showing that its Vaxfectin®-formulated monovalent prophylactic vaccine (encoding HSV-2 glycoprotein D, or gD) protected mice against challenge with 50 times a lethal dose (LD50) of HSV-2, provided sterilizing immunity and inhibited viral counts at both primary and latent infection sites. (
  • A preventive DNA vaccine encoding two Zika structural proteins protected Rhesus macaques from viral infection. (
  • This is a reassuring development and critical advance," said Nelson Michael of the Walter Reed Army Institute of Research in Silver Spring, Maryland, whose team is testing a formalin-inactivated viral particle vaccine . (
  • Although muscle cells normally do not produce antibodies, the viral DNA changes their genetic programming, and the muscles start producing the antibodies. (
  • These are plasmids that usually consist of a strong viral promoter to drive the in vivo transcription and translation of the gene (or complementary DNA) of interest. (
  • Viral vector-based vaccines that induce protective CD8 + T cell immunity can prevent or control pathogenic SIV infections, but issues of preexisting immunity and safety have impeded their implementation in HIV-1. (
  • Five main approaches have emerged in the first flush of COVID-19 vaccine development: viral vectors, protein subunits, inactivated viruses, attenuated viruses, and nucleic acids. (
  • The subsequent development of cidofovir and related molecules and of letermovir for cytomegalovirus infections and the recent approval of tecovirimat for the treatment of smallpox have expanded the range of available countermeasures against DNA viruses, but therapies are still lacking for many important DNA viral diseases. (
  • Is the Subject Area "Viral vaccines" applicable to this article? (
  • Using a next-generation gene delivery technology to the existing and approved mRNA vaccines, the VAX-001 DNA vaccine delivers the information needed inside cells to make the viral protein. (
  • This breakthrough non-viral gene delivery platform allows us to rapidly prototype and advance DNA medicines through the clinical trial process. (
  • In natural HBV infection and in HBV vaccine recipients, the presence of antibodies directed to the surface antigen of the viral envelope protein (anti-HBs antibodies) is a marker of immunity. (
  • And this vaccine can be customized for the different viral strains which cause epidemics in different parts of the world. (
  • Now the host cell contains human DNA as well as genetically engineered viral DNA. (
  • For some 20 years now, scientists working closely with DNA coding for viral proteins have found that these induce strong immune responses in rodents. (
  • One of the key points of the new DNA patch vaccine is that it also contains an adjuvant molecule (could be strands of RNA that resemble viral RNA) that cause inflammation in the area, alerting swarms of immune cells, thus improving immune response. (
  • In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. (
  • The VRC-HIVDNA009-00-VP vaccine used in this study was developed to incorporate HIV genes from multiple virus clades, representing the viral subtypes responsible for about 90% of new HIV infections in the world. (
  • Sardesai NY, Weiner DB (2011) Electroporation delivery of DNA vaccines: prospects for success. (
  • Luxembourg A, Evans CF, Hannaman D (2007) Electroporation-based DNA immunisation: translation to the clinic. (
  • Dupuy LC, Richards MJ, Ellefsen B et al (2011) A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. (
  • Luckay A, Sidhu MK, Kjeken R et al (2007) Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. (
  • Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R (2006) Enhancement of immune responses to an hbv DNA vaccine by electroporation. (
  • Widera G, Austin M, Rabussay D et al (2000) Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. (
  • Albrecht MT, Livingston BD, Pesce JT, Bell MG, Hannaman D, Keane-Myers AM (2012) Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague. (
  • The Vaxfectin®-formulated DNA vaccines administered without electroporation provided equivalent or better immunogenicity than unformulated DNA vaccines followed by electroporation with either constant-voltage or constant-current devices. (
  • They then used electroporation, a process that is just beginning to take hold because it increases the uptake of vaccines in the body. (
  • Rockefeller University Hospital is taking the combination of DNA and electroporation in hopes of developing a vaccine against HIV. (
  • Two such improvements are the use of genetically engineered cytokine adjuvants and plasmid delivery via in vivo electroporation (EP), the latter of which has been shown to increase antigen delivery by nearly 1000-fold compared to naked DNA plasmid delivery alone. (
  • Ichor is dedicated to the clinical application and commercialization of electroporation technology for the delivery of DNA drugs and vaccines to treat and prevent debilitating or life threatening diseases. (
  • Most of these efforts have focused on increasing the delivery of vaccine to antigen-presenting cells using different carriers or by electroporation. (
  • Previous methods of inserting DNA relied on a technique called electroporation . (
  • In a separate animal study, electroporation following injection of unformulated vaccine yielded comparable improvements in antibody responses, but electroporation required anesthesia of the animals while needle-free injection of Vaxfectin(TM)-formulated vaccine was administered safely and tolerably without anesthesia. (
  • Unformulated vaccines were injected with needle and syringe followed in some animals by electroporation using either a constant voltage multi-needle device or a constant current multi-needle device. (
  • Both electroporation devices and the Vaxfectin(TM)/needle-free device combination elicited significant increases in production of gB-specific antibodies compared with unformulated vaccine delivered by needle and syringe alone and all three enhancements elicited comparable production of gB-specific antibodies. (
  • Antigen processing and therefore the immune response to vaccines is generally divided into two systems, although considerable cross-over exists. (
  • Patients will be recruited within the next two months and will be given seven injections under the skin over a five-month period, during which time doctors will assess their immune response to the vaccine and test them for any sideeffects. (
  • A new study by UT Southwestern's Peter O'Donnell Jr. Brain Institute shows that a vaccine delivered to the skin prompts an immune response that reduces buildup of harmful tau and beta-amyloid - without triggering severe brain swelling that earlier antibody treatments caused in some patients. (
  • In addition, the vaccine elicits a different immune response that may be safe for humans. (
  • Dr. Rosenberg's idea was to start with DNA coding for amyloid and inject it into the skin rather than the muscle to produce a different kind of immune response. (
  • The latest study - consisting of four cohorts of between 15 and 24 mice each - shows the vaccine prompted a 40 percent reduction in beta-amyloid and up to a 50 percent reduction in tau, with no adverse immune response. (
  • Capone S, Zampaglione I, Vitelli A et al (2006) Modulation of the immune response induced by gene electrotransfer of a hepatitis c virus DNA vaccine in nonhuman primates. (
  • Researchers will measure the volunteers' immune response to the vaccine, compare its potency with that of more traditional vaccines, and assess its safety, the NIH said. (
  • He said DNA vaccines generate some level of cellular immune response, whereas traditional flu vaccines generate only a humoral immune (neutralizing antibody) response. (
  • This partnership will combine the Entos Fusogenix DNA delivery technology with optimized COVID-19 epitopes from EpiVax to generate a highly effective immune response against the novel coronavirus, while ensuring a high degree of safety. (
  • When the team introduced a new flu strain, the 'universal' vaccine induced an immune response too. (
  • DNA vaccines are the third generation vaccines based on purified plasmid preparations containing transgenes that encode antigenic/therapeutic proteins or peptides capable of triggering an immune response against a wide range of diseases. (
  • Several infectious diseases, such as polio, measles, diphtheria, rubella, mumps and tetanus can be controlled and, in many cases, be eradicated with current vaccines as these have been used to mimic natural infections activating an immune response and consequently an immune protection without any potential harmful effects to patients. (
  • The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say. (
  • DNA vaccines work by injecting genetically engineered plasmid containing the DNA sequence encoding the antigen(s) against which an immune response is sought, so the cells directly produce the antigen, thus causing a protective immunological response. (
  • DNA vaccines have theoretical advantages over conventional vaccines, including the ability to induce a wider range of immune response types. (
  • This DNA is injected into host body and produces protein for which the body generates immune response. (
  • A novel and powerful method for vaccine research, colloquially known as DNA vaccines, involves the deliberate introduction into tissues of a DNA plasmid carrying an antigen-coding gene that transfects cells in vivo and results in an immune response. (
  • These methods involve the deliberate introduction of a DNA plasmid carrying a proteincoding gene that transfects cells in vivo (albeit at a low efficiency) and expresses an antigen causing an immune response (3) . (
  • It was not expected that pure plasmid DNA could be taken up by cells, after parenteral introduction in a simple saline solution (4) , to levels allowing expression of enough protein to induce an immune response. (
  • Two studies from the Peter O'Donnell Jr. Brain Institute demonstrate in animals how a vaccine containing DNA of the toxic beta-amyloid protein elicits a different immune response that may be safe for humans. (
  • The data to be presented will demonstrate the stimulation of the immune response comparing synDNA(TM) based vaccines to traditional plasmid DNA vaccines designed for the prevention of seasonal flu, HIV, smallpox and Hepatitis B. The tests indicate that the immune response triggered by synDNA(TM) vaccines is comparable to, and in some cases more effective than responses mediated by plasmid DNA. (
  • The result has been the development and ongoing refinement of so-called RASVs (for recombinant attenuated Salmonella vaccines), capable of provoking an intense, system-wide immune response and conferring effective immunity. (
  • The paper, titled 'Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial,' found that INO-4800 was immunogenic in all vaccinated subjects, effectively generating an immune response of humoral (including neutralizing antibodies) and/or cellular responses (both CD4 and CD8 T cells). (
  • Injection of this personalized DNA vaccine may be a way to generate an immune response to kill tumor cells. (
  • The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVDNA009-00-VP, in HIV uninfected participants. (
  • It is far more complex to manufacture biological medications (for example, vaccines, antibodies) than it is to produce chemical medications (for example, penicillin or aspirin). (
  • The major concerns with regard to safety are integration of the plasmid DNA into the host genome, adverse immunopathological effects, the formation of anti-DNA antibodies resulting in auto-immune disease and the use of novel molecular adjuvants. (
  • In immunoprophylaxis by gene transfer (IGT), scientists instead hope to modify the DNA of patients to enable them to produce entirely new antibodies. (
  • A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. (
  • The potential of DNA vaccines to act in presence of maternal antibodies, its stability and cost effectiveness and the non-requirement of cold chain have heightened the prospects. (
  • Takis Biotech will use the LinearDNA synthetic genes produced by Applied DNA for each of the five potential vaccines to inoculate mice whose sera will be tested for the presence of antibodies that bind to the purified spike proteins of the novel coronavirus. (
  • Strong protective neutralizing antibodies were also observed in pigs vaccinated with the same vaccine. (
  • The investigators therefore developed a new proprietary neutralization assay (using a mock virus unrelated to FMD to assess the ability of the vaccine-induced antibodies to neutralize virus infection). (
  • These results are the first report of a DNA vaccine producing high titers of neutralizing antibodies against FMD. (
  • Thus, although both DNA vaccines induced high titers of anti-DHBs antibodies, anti-S antibodies induced by the S-DNA construct were highly effective in neutralizing virus infectivity while similar levels of anti-S induced by the pre-S/S-DNA construct conferred only very limited protection. (
  • Immunogenicity test and protection experiments indicated mice were greatly induced generation of neutralizing antibodies and invoked protective effects immunized with intraperitoneal injections of the rabies vaccine. (
  • From the vaccine, you'll get what's called antibodies and T-cells that are your killers. (
  • Inovio's Zika DNA vaccine resulted in seroconversion, or the development of detectable specific antibodies in the blood, in all vaccinated mice. (
  • Due to their rapid and widespread development, DNA vaccines have entered into a variety of human clinical trials for vaccines against various diseases including cancer. (
  • Evidence that DNA vaccines are well tolerated and have an excellent safety profile proved to be of advantage as many clinical trials combines the first phase with the second, saving both time and money. (
  • It is clear from the results obtained in clinical trials that such DNA vaccines require much improvement in antigen expression and delivery methods to make them sufficiently effective in the clinic. (
  • Combined or single strategies to enhance the efficacy and immunogenicity of DNA vaccines are applied in completed and ongoing clinical trials, where the safety and tolerability of the DNA platform are substantiated. (
  • DNA vaccines have been shown to be safe in previous clinical trials for other diseases. (
  • Furthermore, ongoing large-scale phase III clinical trials will be able to determine whether any of these DNA-based therapies are safe and effective to use in subjects with allergic rhinitis and asthma. (
  • DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2014 through 2019 is estimated. (
  • The NIH said the DNA vaccine was brought "from the research bench into clinical trials in less than 6 months. (
  • Nabel said another possibility is that the DNA vaccine, if it succeeds in clinical trials, could be used in combination with a traditional inactivated vaccine, assuming the traditional vaccine was at least modestly immunogenic. (
  • We're looking forward to bringing an effective DNA vaccine to human clinical trials as soon as possible. (
  • The 'universal' vaccine needs more testing, including human clinical trials. (
  • These promising results, coupled with recent clinical trials that have shown enhanced immune responses in humans, highlight the bright prospects for DNA vaccines to address many human diseases. (
  • Clinical trials for DNA vaccines to prevent HIV are underway. (
  • and foot and mouth disease, Aujesky's disease, swine fever, rabies, canine distemper and brucellosis in animals, DNA vaccine clinical trials are underway. (
  • The World Health Organization (WHO) reports that six of the 48 candidate vaccines against SARS-CoV-2 that remain in clinical trials are DNA-based products, as are 14 others in preclinical study ( 1 ). (
  • Free Weekly Vaccines Industry Newsletter Get the latest news about Research Breakthroughs, R&D Trends, Clinical Trials, and Vaccine Production sent straight to your Inbox. (
  • The group demonstrated the effectiveness of this delayed-lysis bacteria in vaccine experiments with a variety of pathogens, including influenza and mycobacteria (causative agent of tuberculosis) and an RASV vaccine developed in the Curtiss lab against infant pneumonia is currently in FDA Phase I clinical trials. (
  • Also, the ongoing clinical trials for human DNA vaccine are considerably propelling the market ahead. (
  • DNA vaccines have progressed rapidly from the conceptual stage to the stage of clinical trials. (
  • This volume contains the proceedings of a meeting devoted to the latest developments in DNA vaccines, from laboratory studies to clinical trials. (
  • However, DNA vaccines have generally been perceived as less immunologically potent than other methods of antigen delivery in human clinical trials, leading to efforts to increase their immunogenicity. (
  • This vaccine is well along in its development, but clinical trials are still more than a year away. (
  • Given that human efficacy trials for MERS vaccines may be challenging due to the low number of yearly cases, animal models such as our NHP model are valuable as a bridge with human data coming from early-phase clinical trials," said Weiner. (
  • Our team is also advancing a COVID-19 vaccine through clinical trials, and we were able to do so in a very short time thanks to our previous experience developing the MERS vaccine," added Weiner. (
  • GeneOne Life Science Inc. is an international DNA vaccine developer and leading contract manufacturer of DNA plasmid-based agents for preclinical and clinical trials for global companies and institutions. (
  • Especially considering this new kind of DNA / RNA vaccine would normally take 15-20 years to roll out, while this one is being rolled out in a matter of months and is already undergoing human clinical trials. (
  • However, the insufficient magnitude of this response has led to the development of approaches for enhancing the immunogenicity of DNA vaccines. (
  • In an effort to further improve the immunogenicity of DNA vaccines, we have explored methods to increase antigen presentation by encoding epitopes with increased MHC class I affinity or by increasing the duration of target antigen expression. (
  • In a separate and important line of experimentation, Tang, De Vit, and Johnston announced in 1992 that it was indeed possible to obtain humoral immune responses against proteins encoded by DNA delivered to the skin by a biolistic device, which has colloquially become known as the "gene gun. (
  • When the vaccine is injected into muscle, cells read the genes and make Zika proteins, which self-assemble into virus-like particles. (
  • Both experimental vaccines, called VRC5283 and VRC5288, were engineered to prompt cells to produce the Zika virus structural proteins premembrane (prM) and envelope (E). Both vaccines included portions of an unrelated virus to improve protein expression. (
  • According to the manufacturer-produced package inserts included with each vaccine batch, many vaccines are made with disturbing ingredients like aborted human fetal proteins, altered DNA material, and even genetically-modified (GM) human albumin. (
  • DALLAS - Nov. 20, 2018 - A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer's disease, according to research that scientists say may pave the way to a clinical trial. (
  • The vaccine is on a shortlist of promising antibody treatments aimed at protecting against both types of proteins that kill brain cells as they spread in deadly plaques and tangles on the brains of Alzheimer's disease patients. (
  • Once inside the body, the DNA instructs human cells to make proteins that act as a vaccine against the virus," the agency said. (
  • Unlike traditional vaccines, a Fusogenix DNA-based vaccine encodes the virus proteins in a DNA plasmid that is then delivered into the patient's own cells by direct fusion. (
  • The DNA vaccine used in the Phase 1 trial incorporates genetic material encoding core and surface proteins from two strains of Ebola. (
  • Currently, all licensed vaccines are based on killed or live-attenuated microorganisms, purified products derived from microorganisms, such as inactivated toxins, purified antigens or polysaccharides conjugated to proteins which are able to efficiently induce humoral (antibody) and/or cellular immune responses essential to prevent and control diseases of global importance ( Table 1 ). (
  • DNA vaccines contain DNA that codes for specific proteins (antigens) from a pathogen. (
  • The DNA is injected into the body and taken up by cells, whose normal metabolic processes synthesize proteins based on the genetic code in the plasmid that they have taken up. (
  • These vaccines are third generation vaccines, and contain DNA that codes for specific proteins from a pathogen. (
  • After losing more than 1 million service days during the Iraq and Afghanistan wars to severe diarrhea in troops, the Defense Advanced Research Projects Agency wants to combat the problem by making drugs based on nucleic acids such as DNA rather than the weakened or dead proteins typically used in vaccines. (
  • Results of the study show that the DNA-encoded vaccine, which used either of the surface proteins known as hemagglutinin (H) or fusion (F), provided protection against measles. (
  • Scientists studying a DNA sequencing autoradiogram of novel recombinant proteins cloned for the production of VaxSyn, an experimental AIDS vaccine. (
  • Administration of plasmid DNA has proven to be an effective means of generating humoral immune responses against various foreign proteins in laboratory and domesticated animals and in some nonhuman primates. (
  • The efficacy of DNA vaccines encoding the duck hepatitis B virus (DHBV) pre-S/S and S proteins were tested in Pekin ducks. (
  • This phenomenon requires further clarification, particularly in light of the development of newer HBV vaccines containing pre-S proteins and a possible discrepancy between anti-HBs titers and protective efficacy. (
  • Vaccines are traditionally based on immunogens delivered as inactivated (Influenza) or attenuated live (smallpox) pathogens , recombinant proteins (Hepatitis B) or virus-like particles (Human Papillomavirus). (
  • An experimental vaccine consisting of five DNA plasmids expressing different combinations and forms of simian immunodeficiency virus-macaque (SIVmac) proteins has been evaluated for the ability to protect against a highly pathogenic uncloned SIVmac251 challenge. (
  • Profectus' therapeutic MAG-pDNA vaccine consists of two plasmid vectors designed to induce immune responses against the env, gag, pol, nef, tat, and vif proteins of HIV. (
  • One treatment approach which attempts to block tumor growth through the disruption of the anigogenic process, is the use of DNA vaccines encoding proteins that are over-expressed during angiogenesis. (
  • To assess the efficacy of inhibiting tumor growth by targeting cells expressing these proteins, BALB/c mice were immunized orally with attenuated salmonella thyphimurium carrying plasmid DNA encoding for empty vector, Flk1, PDGFRβ, or both Flk1 and PDGFRβ followed by i.v. tumor challenge with the colon carcinoma cell line CT26. (
  • There are many advantages to vaccines which work by delivering DNA which instructs cells to produce the specific proteins against which immunity is needed. (
  • A vaccine is a biological preparation which contains a weakened or killed microbial agent, its toxins or its surface proteins, which provides active acquired immunity against the disease caused by the microbe. (
  • To test if these polymer DNA vaccine solicits a response for primates, the scientists engineered DNA that codes for proteins from the simian form of HIV to macaque skin samples cultured in the lab. (
  • When linear DNA enters the nucleus, it does not need to be incorporated into the genome in to be temporarily expressed as the intended proteins product. (
  • Such cooperative strategies delivering vaccine in a single, simple platform result in improved cellular immunity in vivo, including enhanced tetramer responses and IFN-γ secretion by antigen-specific cells. (
  • Although inefficient in generating primary responses to the CE, boosting of the Env CE DNA primed macaques with the intact env DNA vaccine potently augmented pre-existing immunity, increasing magnitude, breadth and cytotoxicity of the cellular responses. (
  • Importantly, the bivalent vaccine generated a balanced immunity against DV1 and DV2 infection, which emits light for development of new type of tetravalent vaccine against dengue viruses," says corresponding author Dr. Jing An (Capital Medical University, China). (
  • We need to determine whether the DNA vaccine can work and can generate a sufficient amount of the right type of immunity to protect against influenza infections. (
  • When responding to an emerging pandemic virus, for which no precisely matched vaccine would be immediately available, the cellular immunity conferred by a DNA vaccine might be of some help, he said. (
  • The scientists, rather than using dead virus, have built a vaccine that stimulates immunity against Avian flu in mice. (
  • One target for growth-inhibitory antibody used in Malaria vaccine strategies is the membrane-associated 19 kDa COOH terminal fragment of merozoite surface protein (MSP119) that plays a crucial role in Plasmodium immunity, and is now a leading malaria vaccine candidate. (
  • Malcolm Skolnick, CEO, states, "DNA vaccines have proven to be a potent means of providing protective immunity against viruses, bacteria and parasites in many species from fish to primates. (
  • SAN DIEGO--( BUSINESS WIRE )--Aegis Life, Inc. announced today that the first participants have been dosed in a Phase 1/2 clinical trial with parent company Entos Pharmaceuticals' (Entos) Covigenix VAX-001, a novel DNA vaccine to stimulate immunity against SARS-CoV-2. (
  • New vaccine modalities are being developed with the aim of generating appropriate humoral and/or cellular immunity. (
  • The salmonella bacterium "knows its way around the gut," and delivers the selected DNA directly to dendritic cells in the intestinal mucosa, which may be particularly effective for providing "mucosal immunity" to prevent HIV infection. (
  • While several vaccine products are being advanced against MERS and other coronaviruses, low-dose delivery and shortened regimes are crucial to rapidly induce protective immunity, particularly during emerging outbreaks, as the current SARS-CoV-2 pandemic has emphasized," said David B. Weiner, Ph.D. , Wistar executive vice president, director of the Vaccine & Immunotherapy Center (VIC) and W.W. Smith Charitable Trust Professor in Cancer Research, who led the study. (
  • Direct injection of plasmid DNA into the muscle induces T- and B-cell responses against foreign antigens. (
  • These modified antigens are candidates for use as prophylactic and therapeutic HIV vaccines. (
  • Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. (
  • Ebola-specific antibody responses against at least one of the encoded antigens were detected in all vaccine recipients. (
  • The fundamental idea behind DNA vaccines (also known as genetic vaccines) is to induce immune responses against recombinant antigens encoded by genetically engineered DNA plasmids expressed in vivo . (
  • DNA can present antigens in a suitable molecular form, ranging from full-length sequence to short MHC class I- or II-binding epitopes, to optimize induction of T-cell responses [ 6 ]. (
  • In this pre-clinical study, DNA vaccine constructs targeting multiple Zika virus antigens were synthetically generated using Inovio's SynCon vaccine technology. (
  • It's an interesting approach that can be applied not just to delivery of DNA-based vaccine antigens, but other small molecules," says Michele Kutzler, an assistant professor at Drexel University College of Medicine, who was not part of the research team. (
  • Cellular and humoral immune responses have been demonstrated after the injection of naked plasmid DNA vaccines into the dermis or muscle tissue of mice [ 5 , 7 ]. (
  • The research published in Alzheimer's Research and Therapy demonstrates how a vaccine containing DNA coding for a segment of beta-amyloid also reduces tau in mice modeled to have Alzheimer's disease. (
  • McCluskie MJ, Brazolot Millan CL, Gramzinski RA et al (1999) Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. (
  • In a new study , researchers inoculated mice with a new DNA vaccine candidate (pVAX1-D1ME) in order to evaluate its efficiency. (
  • Our DNA vaccine candidate induced effective immune responses and protection in mice. (
  • However, it was noted that the end-point titers of anti-DV1 and anti-DV2 in the bivalent vaccine-immunized mice were lower than those in the monovalent vaccine-immunized mice, indicating interference between the DV1 and DV2 vaccine candidates. (
  • The significant protection in mice demonstrated by our vaccine is highly encouraging and strongly supports the importance of this vaccine approach for further study. (
  • New data presented at the conference shows that a 0.1 µg dose of the prophylactic vaccine provided 100% protection of mice against challenge with 50 times a lethal dose (LD50), and a 100 µg dose of the prophylactic vaccine provided 100% protection of mice against challenge with 500 times a lethal dose (LD50). (
  • Data obtained in mice and rabbits demonstrated that DNA vaccines formulated with the company's Vaxfectin® adjuvant provided superior immunogenicity compared to other formulations. (
  • A plasmid-based vaccine against the virus is immunogenic in mice and protects Rhesus macaques against infection, researchers report. (
  • The vaccine cured up to 60% of mice with melanoma. (
  • showed that inoculation of mouse-derived tumor DNA induced tumors and led to seroconversion in injected mice ( 4 , 5 ). (
  • In 1993, Jeffrey Ulmer and co-workers at Merck Research Laboratories demonstrated that direct injection of mice with plasmid DNA encoding a flu antigen protected the animals against subsequent experimental infection with influenza virus. (
  • To validate the use of Tie-2 as a target, human Tie-2 was used as a xenogenic vaccine in mice. (
  • Preliminary studies suggest that immunisation of balb/c mice by gene gun with DNA from the extracellular region of Tie-2 resulted in cessation of tumor growth. (
  • To determine if we could design a syngeneic vaccine that would work in both mice and humans a conserved region of Tie- 2 was cloned. (
  • Using a gene gun HLA-A2 transgenic mice were immunized with the Tie-2 DNA construct. (
  • Dr. Chen comments, "We have successfully conducted tests of synDNA(TM) based vaccines in mice, rabbits and non-human primates. (
  • Antibody responses were first demonstrated in mice, induced by particle bombardment with gold beads coated with DNA encoding human growth hormone and human a -1 antitrypsin (3). (
  • The experimental vaccine described in the new research demonstrated complete protection from influenza in mice, but Wei Kong, the leading author of the new study stresses that the innovative technique could be applied to the rapid manufacture of effective vaccines against virtually any infectious invader at dramatically reduced cost and without risk to either those vaccinated or the wider public. (
  • Scott said the vaccine was used in mice, and they were fully protected from one-hundred times the lethal dose of the neurotoxin. (
  • When mice were immunized with either the PDGFRβ or Flk1 vaccine alone, they displayed a significant decrease in the number of lung metastases in comparison to controls, whereas mice receiving a Flk1 plus PDGFRβ combination vaccine showed a more pronounced decrease in the number of lung metastases compared to all other treatment groups. (
  • Upon co-culture of the effector splenocytes with the Hevc-Flk1 target cells, we found that mice immunized with the Flk1 plus PDGFRβ combination vaccine induced the greatest cytolysis against Hevc-Flk1 target cells followed by mice immunized with either the Flk1 or PDGFRβ vaccine. (
  • Together, these results suggest that the use of a combined Flk1 plus PDGFRβ vaccine provides for superior protection from tumor progression than by immunizing mice against either target alone. (
  • With robust antibody and killer T cell responses generated by our vaccine in mice, we will next test the vaccine in non-human primates and initiate clinical product manufacturing. (
  • Here, we show that a DNA vaccine encoding the first 725 amino acids (S1) of MERS-CoV spike (S) protein induces antigen-specific humoral and cellular immune responses in mice. (
  • TY - JOUR T1 - DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. (
  • This review gives an overview of the mechanisms, preclinical and clinical efficacy of DNA vaccines, and point out the limitations of the first generation of such vaccines, and some of the promising second-generation developments. (
  • Many aspects, such as antigen expression and especially vector design, are under study because of their great influence on immunogenicity and efficacy of DNA vaccines. (
  • For licensing purposes, besides the immunogenic aspects, deoxyribonucleic acid (DNA) vaccines present safety considerations that must be critically assessed during preclinical or/and clinical safety studies. (
  • This work describes 12 regions in HIV Env that are highly conserved throughout the known HIV M Group sequences (Env CE), and are poorly immunogenic in macaques vaccinated with full-length Env expressing DNA vaccines. (
  • CE are poorly immunogenic in env DNA vaccinated macaques. (
  • They also evaluated the immunoprotective potential of a combined (bivalent) DNA vaccine, which was found to generate a balanced immunogenic response to two serotypes of dengue virus (DV1 & DV2). (
  • Nabel said the new technique has the potential to speed up flu vaccine production, but he stressed that investigators first must show that the vaccine is immunogenic and safe. (
  • Inoculation of plasmid DNA, encoding an immunogenic protein gene of an infectious agent, stands out as a novel approach for developing new generation vaccines for prevention of infectious diseases of animals. (
  • Killed pathogen strains or vaccines produced from pathogen subunits sacrifice some of their immunogenic effectiveness for enhanced safety, and may require subsequent booster doses to ensure continued effectiveness. (
  • VAC-3S, an immunotherapeutic vaccine that mimics a highly conserved motif in the HIV-1 gp41 envelope protein, proved immunogenic in a 32-week trial that involved 33 adults taking suppressive antiretroviral therapy [1]. (
  • VAC-3S immunotherapeutic HIV vaccine combined with ART is immunogenic and safe. (
  • Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection. (
  • NIH's National Institute of Allergy and Infectious Diseases (NIAID) is supporting the research and development of multiple Zika vaccine candidates. (
  • Scientists from NIAID's Vaccine Research Center developed 2 experimental DNA vaccines against Zika virus. (
  • The researchers vaccinated groups of rhesus macaques using the 2 different Zika DNA vaccines in different doses. (
  • These studies and others will inform the next steps of Zika vaccine development. (
  • Ted Pierson and Barney Graham , both of the National Institute of Allergy and Infectious Diseases (NIAID), and their colleagues created two DNA vaccine versions, both with genes encoding Zika pre-membrane and envelope genes, plus an additional short Japanese encephalitis virus sequence into a cytomegalovirus promoter-based plasmid vector. (
  • When challenged with the Puerto Rican Zika strain eight weeks later, 17 of 18 animals immunized with either the single 4 mg dose or two 1 mg doses showed no detectable virus, while one animal contained a low level of Zika DNA. (
  • No DNA vaccine against Zika has yet been approved for human use. (
  • An experimental DNA-based vaccine protected monkeys from infection with the birth defects-causing Zika virus, and it has proceeded to human safety trials, researchers report. (
  • In 2016 a DNA vaccine for the Zika virus began testing in humans at the National Institutes of Health. (
  • Separately, Inovio Pharmaceuticals and GeneOne Life Science began tests of a different DNA vaccine against Zika in Miami. (
  • U.S. health officials have begun enrolling volunteers for critical next-stage testing of an experimental vaccine to protect against Zika, the mosquito-borne virus that can cause devastating birth defects in pregnant women. (
  • When we have outbreaks like Ebola or Zika, there are scientists in research labs working day in and day out to find answers, treatments or vaccines to protect us. (
  • Feb. 17, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses, demonstrating the potential for a SynCon® vaccine to prevent and treat infections from this harmful pathogen. (
  • Inovio is developing its Zika vaccine with GeneOne Life Sciences (KSE:011000) and academic collaborators. (
  • We plan to initiate phase I human testing of our Zika vaccine before the end of 2016. (
  • Inovio's Zika program builds on its extensive previous preclinical development experience with flavivirus-related vaccines. (
  • No vaccine or therapy currently exists for the Zika virus. (
  • Enhanced neutralizing antibody response induced by respiratory syncytial virus prefusion F protein expressed by a vaccine candidate," Journal of Virology , vol. 89, no. 18, pp. 9499-9510, 2015. (
  • Further, previously tested vaccines -including the DNA-based candidate being tested on healthy volunteers-similarly have not shown signs of antibody-dependent enhancement (ADE). (
  • A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck's rVSV-ZEBOV vaccine. (
  • By Porter Novelli, Life Sciences, Vical Incorporated (Nasdaq:VICL) announced today that an Ebola vaccine candidate administered using Vical's proprietary DNA delivery technology was safe and well tolerated, and produced both antibody and T-cell Ebola-specific responses in all healthy volunteers who received the full 3 doses of vaccine. (
  • The high rates of immune responses at all dose levels in this initial human Ebola vaccine study support continued development of this vaccine and further evaluation of our technology for potential additional biodefense and emerging disease applications," said David C. Kaslow, M.D., Vical's Chief Scientific Officer, "particularly where antibody responses may be protective. (
  • Importantly, the multi-subtype DNA vaccines targeting three or four subtypes simultaneously were able to induce equally strong levels of antibody titers compared to the single-subtype vaccines. (
  • Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, 'INOVIO's DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2. (
  • Thus, the DNA vaccine raised both neutralizing antibody and cytotoxic T-lymphocyte responses and provided some attenuation of the acute phase of infection, but it did not prevent the loss of CD4+ cells. (
  • MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that in a recently completed animal study, a DNA vaccine formulated with the company's patented Vaxfectin(TM) adjuvant and delivered by needle-free injection yielded significantly higher antibody responses than an unformulated DNA vaccine delivered by needle and syringe. (
  • Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced a collaboration with EpiVax, Inc. (EpiVax), a world leading informatics and immunology biotechnology company with a proven track record in vaccine development. (
  • Senior author Diane Griffin, MD, PhD, professor and chair, Molecular Microbiology and Immunology , Johns Hopkins School of Public Health, says, "This is the first step toward developing a new measles vaccine that can potentially be used for immunizing infants in developing countries. (
  • They found that the vaccine candidate was able to induce persistent humoral and cellular immune responses and provided efficient protection against lethal challenge from one of the four serotypes of dengue virus (DV1). (
  • But will that not limit the chances of my vaccine to induce an immune respond? (
  • The breadth of applications for DNA vaccines thus ranges from prophylactic vaccines to immunotherapy for infectious diseases, cancer, and autoimmune and allergic diseases. (
  • The major markets for DNA vaccines, including infectious diseases, cancers, animal health, allergies and biodefense, are analyzed, and the main companies in these fields are highlighted. (
  • This new POWV vaccine candidate, described in a paper published today in PLOS Neglected Infectious Diseases , is one of many emerging infectious disease DNA vaccine discoveries being advanced by the Vaccine and Immunotherapy Center at The Wistar Institute. (
  • Kar Muthumani, Ph.D., former associate professor and director of the Laboratory of Emerging Infectious Diseases at The Wistar Institute, and senior author on the study, collaborated with the laboratory of David B. Weiner, Ph.D., executive vice president and director of Wistar's Vaccine and Immunotherapy Center, to design and test this synthetic DNA vaccine. (
  • The vaccine was designed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. (
  • The Phase 1, randomized, placebo-controlled, dose-escalation study, the first human trial for any Ebola vaccine, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and conducted at the NIH Clinical Center. (
  • DNA Vaccines for Emerging Infectious Diseases: What If? (
  • In this review, a brief survey is undertaken of the experimental models and preclinical work on DNA vaccines to contribute to a greater awareness of the possibilities for emerging infectious diseases. (
  • To advance this quest, a research team led by Roy Curtiss, director of the Center for Infectious Diseases and Vaccinology, and Wei Kong, a research assistant professor, at Arizona State University's Biodesign Institute have taken a dramatic step forward, revealing the design of a universal platform for delivering highly potent DNA vaccines, by employing a cleverly re-engineered bacterium to speed delivery to host cells in the vaccine recipient. (
  • Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed Phase 1 clinical data from the first cohort of 40 participants for its COVID-19 DNA vaccine candidate, INO-4800, in EClinicalMedicine , an open access clinical journal published by The Lancet. (
  • Anyone injected with a DNA vaccine will undergo permanent and unknown genetic changes.The National Institute of Allergy and Infectious Diseases (NIAID) has launched efforts to create a vaccine that would protect people from most flu strains, all at once, with a single shot. (
  • Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, said "a substantial amount" of the DNA was found in the vaccine. (
  • INO ), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800, its COVID-19 vaccine candidate. (
  • A new study reports the synergistic recruitment, expansion, and activation of DCs in vivo in a mouse model through covaccination with plasmids encoding macrophage inflammatory protein-1α (MIP-1α), fms-like tyrosine kinase 3 ligand (Flt3L), and the DNA vaccine. (
  • Plasmids are small, circular, double-stranded DNA molecules, which are distinct from a cell's chromosomal DNA. (
  • LABVaccFish showed that LAB can deliver DNA plasmids to fish cells. (
  • The vaccine used in the Phase 1 trial vaccine included three plasmids (closed loops of DNA), one each encoding the surface glycoprotein (GP) from the Zaire strain of Ebola, GP from the Sudan/Gulu strain, and the internal nucleoprotein (NP) from the Zaire strain. (
  • engineering of DNA vaccines using molecular adjuvant plasmids. (
  • Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria. (
  • Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. (
  • Thus, it is still necessary to develop safer, more economical and effective vaccines against dengue infection specifically. (
  • Fusogenix technology effectively and safely delivers nucleic acid cargo directly inside cells using advanced and proprietary lipid formulations, making it the ideal platform to develop and manufacture hundreds of millions of doses of safe, stable and effective vaccines. (
  • However, the development of effective vaccines against other viruses (e.g. (
  • The use of naked plasmid DNA as vaccine to elicit the immune system against disease provides a variety of practical benefits for large-scale vaccine production that are not as easily manageable with other forms of vaccines including recombinant protein or whole tumor cells [ 9 , 10 ]. (
  • Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. (
  • These cells recognize the DNA fragment and transcribe it into an RNA fragment capable of inducing production of the SARS-CoV-2 spike protein. (
  • With this DNA vaccine, our cells temporarily become factories producing the spike protein. (
  • The controversial MMR II vaccine also reportedly contains a genetically-engineered human protein known as Recombumin, or recombinant human albumin, that most parents are unaware is being injected into their babies. (
  • MMR II is the only known vaccine that contains GM human protein, according to NVIC, but its unique presence in this contentious combination vaccine could help explain the unusual uptick in vaccine-induced neurological damage associated with it in recent years. (
  • According to NVIC, there are three main sources of human protein in vaccines: fetal cell lines, human albumin derived from human blood, and human albumin genetically engineered from yeast. (
  • By comparison, mRNA vaccines send their chemically synthesized mRNA payload (bundled with spike protein-manufacturing instructions) directly into the cytoplasm. (
  • Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus," Vaccine , vol. 32, no. 44, pp. 5866-5874, 2014. (
  • Scientists at The Wistar Institute have designed and tested the first-of-its-kind synthetic DNA vaccine against Powassan virus (POWV), targeting portions of the virus envelope protein. (
  • Alternatively, the DNA may be encapsulated in protein to facilitate cell entry. (
  • If this capsid protein is included in the DNA, the resulting vaccine can combine the potency of a live vaccine without reversion risks. (
  • Also, the induction of immune responses by DNA vaccines is inconclusive due to the lack of knowledge regarding the concentration of the protein expressed in vivo . (
  • As the team reports in a recent paper in Langmuir ( 'Superparamagnetic Nanoparticles for Effective Delivery of Malaria DNA Vaccine' ), the high transfection potential of these nanoparticles as demonstrated by the expression of MSP119 protein in vitro indicated the possibility of using these vectors with magnetofection technique as an efficient malaria gene MSP119 delivery carrier. (
  • Based on the type, the DNA vaccines market is divided into recombinant protein and genetic. (
  • This large share is attributed to the presence of high number of recombinant protein vaccines in the market. (
  • However, many vaccine developers are using that strategy, and targeting only the S protein is likely to limit vaccine efficacy and durability. (
  • DNA vaccines have distinct advantages: They can be manufactured far more easily than vaccines composed of an inactivated pathogen, subcellular fraction, or recombinant protein. (
  • It is now possible to change the sequence of an ntigenic protein, or to add heterologous epitopes, by simply introducing mutations to the plasmid DNA. (
  • The immunogenicity of the modified protein can be directly assessed after injecting the plasmid DNA. (
  • Canine Melanoma Vaccine, DNA (Trade name: Oncept) consists of highly purified plasmid DNA capable of expressing the human tyrosinase protein in transfected canine cells. (
  • Hepatitis B virus (HBV) vaccines which contain the small envelope protein (S-HBs) of the virus provide significant protection against HBV infection. (
  • DNA vaccines are based on the delivery of genes encoding a specific protein antigen that is transcribed and translated by host cells [ 4 , 5 ]. (
  • It is a recombinant HPV DNA (rDNA) - genetically engineered - to be inserted into yeast cells for VLP (virus-like-particle) protein production. (
  • These results demonstrate that a DNA vaccine encoding MERS-CoV S1 protein induces strong protective immune responses against MERS-CoV infection. (
  • Historically, Wolff and colleagues [ 4 ] first demonstrated that long-term gene expression in mouse skeletal muscle could be achieved with direct intramuscular injection of plasmid DNA. (
  • The DNA vaccines are simple rings of DNA containing a gene encoding an antigen, and a promoter/terminator to make the gene express in mammalian cells. (
  • We examine DNA synthesis, biotechnology and pharmaceuticals firms, strategic industry alliances, and the role of gene delivery and synthesis technologies. (
  • The experimental vaccine uses a modified version of the hemagglutinin gene from a recent strain of the deadly H5N1 virus, the NIH reported. (
  • As gene-based vaccines are being designed and tested at unprecedented speeds to fight COVID-19, scientists wonder if this will be the technology's make-or-break moment. (
  • They designed and produced a 'Gene Gun', which releases a painless puff-like injection of DNA into the skin, which goes directly into the skin cells. (
  • Vical has secured a nonexclusive license from the NIH to proprietary gene sequences used in the vaccine. (
  • Here is the punchline: "The viruses invade human cells with their DNA payloads, and the synthetic gene is incorporated into the recipient's own DNA. (
  • Read that again: "the synthetic gene is incorporated into the recipient's own DNA. (
  • Within the past decade, four successful DNA plasmid products have been licensed for animal use: one for the treatment of West Nile virus in horses ( 7 ), one against hematopoietic necrosis virus in salmon ( 8 ), one for the treatment of melanoma in dogs ( 9 ), and a growth hormone-releasing hormone (GHRH) gene therapy for swine ( 10 ). (
  • They altered the DNA of cowpox virus by inserting a gene from other viruses (namely Herpes simplex virus, hepatitis B and influenza). (
  • SPIONs/PEI complexes produced at acidic conditions showed the best DNA binding and gene transfection efficiency compared to those generated under neutral pH, possibly due to the protonated structure of the branched polymer that entrapped and protected the DNA. (
  • The cellular uptake of SPIONs/PEI/DNA also increased dramatically with application of external magnetic field during the gene transfection process. (
  • Now, for Aegis Life, developing a vaccine or therapeutic is just a matter of identifying the right DNA plasmid, inserting it into the gene-delivery cassette, and using that to conduct animal studies - a process almost like programming software. (
  • At Aegis Life, we develop the next generation of DNA vaccines and therapies for the world's most dangerous diseases, leveraging Fusogenix gene delivery platform, developed by parent company Entos Pharmaceuticals. (
  • I have to amplify the gene from the N- to the C-terminal to increase the immunogenecity of my vaccine. (
  • The experimental 'DNA vaccine' that will inject a person with synthesized genes will permanently alter DNA, as the synthetic gene is incorporated into the recipient's own DNA. (
  • In all forms of gene therapy, DNA exerts its influence from within the nucleus. (
  • Vaccine manufacturers are allowed to use cell material that comes from the bodies of mammals, including humans, monkeys, cows, pigs, dogs and rodents, as well as cells from birds and insects, to make either experimental or currently licensed vaccines. (
  • DNA vaccines have been licensed in veterinary medicine and have promise for humans. (
  • Limitations include the relatively poor immunogenicity of naked DNA in humans and the profound differences in HSV-2 pathogenesis between host species. (
  • A vaccine developed elsewhere showed promise in the early 2000s, but when tested in humans, it caused brain swelling in some patients. (
  • Although this method is still in development and no licensed DNA vaccine is currently available for humans, it would offer a number of potential advantages including inexpensiveness, improved vaccine stability and ease of production. (
  • Alex Jones showed a clip from the 1982 John Carpenter film The Thing where an alien organism takes over the cells of dogs and humans, similar to the way the globalists want to take over human cells with synthetic nanotech vaccines. (
  • While the reasons for this inconsistency have yet to be fully elucidated, several attempts have been made to enhance immunogenicity in humans, resulting in studies that have provided a wealth of constructive information that may guide research efforts toward the development of improved DNA products. (
  • This review will focus on specific combined DNA vaccine approaches to improving immunogenicity in humans. (
  • Currently, the researchers are engaged in developing genetic vaccines for humans. (
  • The majority of DNA vaccines available in the market are targeted for humans. (
  • This review summarizes the types of DNA vaccine vectors in common use, the immune responses and protective responses that have been obtained in animal models, the safety considerations pertinent to the evaluation of DNA vaccines in humans and the very limited information that is available from early clinical studies. (
  • However, despite all the practical advantages, DNA vaccines face challenges in inducing potent antigen specific immune responses and protection in humans. (
  • The papers, written by leaders in the field, focus on the current state of DNA vaccines in humans and other large animals. (
  • Results on rodents and primates so far have been fantastic, and if the method can be deemed transmissible to humans than the DNA vaccine might overcome not only the safety risks associated with vaccines for certain types of infections and diseases, like HIV , but also those associated with stability. (
  • More tests on non-primate animals will continue in order to gather data, but if found promising and transmittable to humans, the DNA vaccine might prove to be a huge breakthrough for medicine. (
  • The contaminant material is DNA from porcine circovirus 1, a virus from pigs that is not known to cause disease in humans or animals, Hamburg said. (
  • Both vaccines were highly effective when given in 2 doses. (
  • All but 1 of the 18 animals that received 2 doses of vaccine (94%) had no detectable virus in their blood. (
  • Researchers plan to evaluate both experimental vaccines in people to test a variety of regimens and doses for safety and immune responses. (
  • Parents being told by federal health officials to give their babies three doses of live rotavirus vaccine before six months of age expect those vaccines and others to be free from adventitious agent contamination because the FDA legally requires vaccine manufacturers to adhere to binding regulations rather offering companies non-binding recommendations. (
  • Subjects received three doses of vaccine or placebo at one-month intervals via intramuscular needleless injection. (
  • Three cohorts tested progressively higher doses of the vaccine at 2 mg (5 subjects), 4 mg (8 subjects), or 8 mg (8 subjects with 6 receiving the full three doses). (
  • The vaccine was well tolerated, with no severe adverse reactions to the vaccine reported at any of the doses tested. (
  • This is a dose escalation study to evaluate the safety, immunogenicity, and efficacy of 3 doses of HSV plasmid DNA (pDNA) vaccines formulated with Vaxfectin® in subjects with a minimum of 1 year of reported history of genital herpes, and either 2 to 9 recurrences within the year prior to screening, or 2 to 9 recurrences per year prior to starting suppressive therapy. (
  • By delivering the DNA vaccine using a recombinant attenuated bacterium, we can get 10,000-100,000 doses per liter of culture," Kong says, an improvement of 3-4 orders of magnitude over use of the naked plasmid DNA, which must be painstakingly isolated from bacteria before injection. (
  • facilitate distribution of vaccine doses to the US and international markets. (
  • It will assess the safety and immunogenicity of a fixed dose of the Profectus therapeutic MAG-pDNA vaccine administered alone or with low, intermediate, and high doses of GENEVAX™ IL-12 pDNA adjuvant when delivered with the TriGrid device. (
  • According to World Health Organization (WHO), out of the total number of children worldwide who did not receive the required three doses of diphtheria-tetanus-pertussis vaccines, more than 40% were from sub-Saharan Africa. (
  • To evaluate the safety and efficacy of 4 doses of VCL-HB01, a therapeutic HSV plasmid DNA vaccine formulated with Vaxfectin® in HSV-2-seropositive adults with a reported history of symptomatic genital herpes for at least one year. (
  • Two different doses of the vaccine will be tested. (
  • All new vaccine candidates should therefore be thoroughly tested in target animals, keeping in mind that for food producing animals, the products will be consumed. (
  • Finally, we try to translate the DNA vaccine candidates for further clinical application. (
  • Production of all vaccine candidates is expected to be completed in April at Applied DNA's LinearDNA production facility in New York. (
  • The full characterization of the immunological space created by myeloid cell crosstalk will likely provide clues to improve the efficacy of HIV vaccine candidates. (
  • Vaccine candidates that are simple to deliver, well tolerated, and can be readily deployed in resource-limited settings will be important to achieve control of infection. (
  • Inovio previously published robust immunogenicity and challenge protection data for its SynCon dengue and WNV vaccine candidates. (
  • Here, we review preclinical studies on the DNA-prime/modified vaccinia Ankara (MVA)-boost vaccine modality for HIV. (
  • Aegis and Entos have also developed a second DNA vaccine candidate, in preclinical studies now, called Covigenix VAX-002, that is designed as a pan-coronavirus and emerging variant vaccine. (
  • Factors like increasing investments for third-generation vaccines, increasing adoption in animal healthcare and potential application of these vaccines in identifying growing prevalence of diseases is influencing the market growth. (
  • The treatment, which uses viruses carrying human DNA to direct the body's natural defences against cancer cells, is the first prostate cancer vaccine ever to reach late stage "phase three" trials in Europe. (
  • Scientists added four human genes to the DNA of the viruses which caused them to develop chemical signals which are found in cancerous cells but not healthy ones. (
  • While we may not, as yet, be consuming other human beings per se , we are being injected via many vaccines with aborted fetal cells that could contain residual DNA, viruses and bacteria. (
  • consequences of tampering with human DNA, uncontrollable viruses, and bacteria. (
  • The science community marginalizes the possibility that residual DNA could pose health risks for those injected with vaccines using human cell lines, yet the fact remains that history has shown us this is not only a possibility, but that residual viruses and DNA disruptions from residual activity is a very real possibility. (
  • As of yesterday, we know that DNA from two pig viruses, one of which has been linked to a wasting disease in baby pigs, has been identified in Rotateq vaccine. (
  • The FDA approved manufacturing process for RotaTeq and Rotarix allows use of African Green Monkey kidney cells, cow serum and a pig pancreatic enzyme, which presents opportunities for adventitious agent contamination with, for example, the prion that causes mad cow disease or DNA from viruses that infect pigs and monkeys. (
  • And could there be other animal viruses DNA in rotavirus vaccines that still has not been detected with currently used technology? (
  • As has been mentioned today, contamination of vaccines with animal viruses is not new. (
  • Flu vaccines, according to the best scientific evidence available today, will only work against 10% of the circulating viruses that cause the symptoms of seasonal epidemic influenza. (
  • Conventional flu vaccines use viruses that are grown in chicken eggs and administered in weakened or killed form, the NIH noted. (
  • Nabel and his colleagues have previously shown the efficacy of DNA flu vaccines in lab animals, including animals exposed to H5N1 viruses and the H1N1 virus that caused the 1918 pandemic, the NIH said. (
  • Dr. Ho says, "It could be that the vaccine in its current form could protect against most of the H5N1 viruses out there. (
  • These viruses are then injected into patient (usually into muscle tissue), where they transfer the genetically engineered DNA to the muscle cells. (
  • Many companies make vaccines--particularly those for influenza--with viruses grown in chicken eggs. (
  • HIV-1 is a genetically diverse collection of viruses, making it a moving target in vaccine development. (
  • The vaccine is a DNA vaccine, which is a synthetic vaccine, meaning we don't use any cells or any viruses,' Scott said. (
  • A DNA vaccine could be made to tackle just about any kind of disease, and as antibiotics become ever difficult to manufacture due to drug resistant viruses and diseases , this might prove to be the ultimate weapon. (
  • In the next four to six weeks, the drug agency will convene an advisory committee to make recommendations and seek input on the use of new techniques for identifying viruses in vaccine, Hamburg said. (
  • The use of fetal tissue in vaccine development is the practice of researching, developing, and producing vaccines through growing viruses in cultured (laboratory-grown) human fetal cells. (
  • They are still used to grow vaccine viruses today. (
  • HPV vaccines protect against two to seven high-risk strains of this family of viruses and may prevent up to 90% of cervical cancers. (
  • The successful outcome of this project will be an approved COVID-19 DNA vaccine that will provide broad-based protection against coronaviruses and also a potent cell-based activity that will mitigate active COVID-19 infections. (
  • citation needed] On February 27, 2021, an EUA was issued by the US FDA for the Janssen COVID-19 DNA vector vaccine, following EMA recommendation of the AstraZeneca DNA vector vaccine. (
  • A participant receives a dose marking the start of Phase I trials for Aegis Life/Entos Pharmaceuticals COVID-19 DNA vaccine, Covigenix VAX-001. (
  • We're excited that the Phase 1/2 trials have begun with our COVID-19 DNA vaccine," said John Lewis, CEO, Aegis Life. (
  • Herein, we detail lessons learned investigating candidate DNA vaccines in the progesterone-primed female mouse vaginal model of HSV-2 infection as a guide to investigators in the field. (
  • The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. (
  • There are no vaccines or therapies available to treat or prevent this emerging infection. (
  • Given the risk of serious complications from POWV and the 300% increase in incidence of POWV infection over the past 16 years, we will continue efforts to advance this urgently needed emerging infectious disease vaccine candidate towards the clinic,' said Weiner. (
  • The vaccine is being developed by MicroGeneSys and is undergoing trials as a treatment of HIV-positive patients & as a potential vaccine against HIV infection. (
  • I am not aware of any information that suggest that vaccine will make the virus level go higher but usually we don't give vaccine to people who already have the infection. (
  • The DNA immunizations did not prevent infection or protect against CD4+ cell loss. (
  • The vaccine prevents infection from a neurotoxin that's produced by a strain of bacteria called Clostridium botulinum. (
  • The vaccine would protect the U.S. military against what has been deemed a bio-weapons agent, teaching the recipient's immune system to fight off a potentially deadly infection. (
  • One historical cell line used in rubella vaccines was obtained from a fetus aborted due to infection with rubella. (
  • A presentation by Sean M. Sullivan, Ph.D., Vical's Executive Director of Pharmaceutical Sciences, "Development of Vaxfectin®-formulated HSV-2 Plasmid DNA Vaccines for Prophylactic and Therapeutic Applications," highlights the latest preclinical data from the company's herpes simplex virus type 2 (HSV-2) vaccine development program. (
  • In the last 25 years, DNA vaccines emerged as promising in prophylactic and therapeutic settings. (
  • Moreover, for veterinary vaccines intended to be used in husbandry animals, food safety aspects will become an important issue. (
  • With this in mind, this review aims to giving a conceptual approach of DNA vaccines, explaining their mechanisms of action and listing the already licensed veterinary DNA vaccines presented in the market. (
  • citation needed] Several DNA vaccines have been tested for veterinary use. (
  • A veterinary DNA vaccine to protect horses from West Nile virus has been approved. (
  • The vaccine was evaluated by the Canadian Centre for Veterinary Biologics of the Canadian Food Inspection Agency for licensing in Canada. (
  • The market is especially gaining popularity in the animal healthcare sector as the vaccines help in the insurance and counteractive action for many veterinary diseases. (
  • Major areas of concern are vaccine delivery, designing of suitable vectors and cytotoxic T cell responses. (
  • Hence, DNA vaccine vectors have been developed to maximize the level of antigen expression. (
  • This recombinant DNA technology is being spearheaded by companies like Inovio, GlaxoSmithKline, Sanofi and Moderna. (
  • The DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. (
  • I have to produce a vaccine using recombinant DNA technology. (
  • This development will not only make vaccinations less harrowing, but also allow for developing and delivering vaccines for diseases too dangerous for conventional techniques . (
  • Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. (
  • Thus, to establish criteria for guidance and regulations for industry and licensing authorities, a project has been initiated to assess such risks of plasmid DNA vaccinations. (
  • Subjects will receive 2 vaccinations with the Biojector® 2000, and will be followed for 6 months to evaluate the safety of and the immune system's response to the vaccine. (
  • She believes the 'universal' vaccine could eventually eliminate the need for yearly flu vaccinations. (
  • in this case, ranging from 1000 - 100,000) to all the vaccine subtypes after only one or two vaccinations. (
  • The therapy is a combination of the virus used in a smallpox vaccine and a strain of the fowlpox virus, which causes diseases in poultry. (
  • Is there a relationship between the burgeoning epidemic of chronic diseases and the vaccine trials that took place decades ago? (
  • Yongping Jiang , Hongbo Zhang , Guojun Wang , Pingjing Zhang , Guobin Tian , Zhigao Bu , and Hualan Chen "Protective Efficacy of H7 Subtype Avian Influenza DNA Vaccine," Avian Diseases Digest 5(s1), (1 March 2010). (
  • Development of this vaccine technology has the potential to improve our production capacity for vaccines to prevent seasonal influenza and other diseases," NIAID Director Anthony S. Fauci, MD, commented in the news release. (
  • Moreover, vaccines for many pathogens, such as the human immunodeficiency virus and the agents of malaria and tuberculosis are until now ineffective or unavailable [6] , being the lacky of vaccines to prevent or treat these complex diseases one of the major public health problems in the world. (
  • A global vaccine experiment of the type I'm describing here has another bonus for the planners: those people who fall ill or die can be written off as having suffered from various diseases and disorders which "have nothing to do with vaccines. (
  • In 1983, Enzo Paoletti and Dennis Panicali at the New York Department of Health devised a strategy to produce recombinant DNA vaccines by using genetic engineering to transform ordinary smallpox vaccine into vaccines that may be able to prevent other diseases. (
  • The report also includes pipeline analysis based on the type of phase, therapeutic indications, and type of diseases for which the vaccines have been designed, such as infectious and vector borne diseases, and various types of cancers. (
  • DNA vaccines have been approved by USDA as treatments for diseases in fish, horses, dogs, and non-human primates. (
  • It researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. (
  • Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. (
  • He added: "Right now this is the only cancer vaccine in this late stage of development with this large-scale potential for patients to benefit from it. (
  • Work on the development of DNA vaccines continues aspace for a huge range of potential applications and this book will be invaluable for any laboratory involved in research in this field. (
  • SCPI has affirmed that they are continuing to study the impact of residual human fetal DNA in vaccines on the brain development and autism in children, and will present their studies at the International Society for Autism Research in May 2010. (
  • These results are encouraging for the future development of a tetravalent vaccine that could provide efficient protection against all four serotypes of the virus. (
  • The vaccine now being tested is similar to other DNA vaccines in development, including vaccines for HIV, Ebola, SARS (severe acute respiratory syndrome), and West Nile virus. (
  • A presentation by Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development, "Phase 2 Clinical Trial Results of a Therapeutic DNA Vaccine, TransVax TM , for Control of Cytomegalovirus in Hematopoietic Cell Transplant Recipients," features the most advanced clinical data presented at the conference. (
  • A poster presented by Jukka A. Hartikka, Ph.D., Vical's Associate Director of Vaccinology, "Preclinical Evaluation of the Immunogenicity of Plasmid DNA-based Prophylactic Vaccines for Human Cytomegalovirus," detailed the preclinical results supporting clinical development of the company's CyMVectin TM prophylactic CMV vaccine. (
  • Our processes allow rapid development and manufacturing of vaccines without handling potentially dangerous pathogens. (
  • The Ebola DNA vaccine under development by the NIH may be eligible for this stockpiling program. (
  • April 3, 2020 -- Applied DNA and Takis Biotech have added a fifth candidate to their COVID-19 vaccine development program, increasing the chances of a successor emerging. (
  • Aegis Life spun out of Canadian biopharmaceutical company Entos Pharmaceuticals early in 2020 to pursue US-based research and development (R&D) of a pancoronavirus DNA vaccine. (
  • Jiang explains how DNA-based platforms might facilitate vaccine development and manufacture and how drug companies are addressing problems with payload delivery that beset early attempts to commercialize nucleic-acid vaccines. (
  • With more than 200 candidate vaccines in development, clinical evaluation, and beyond ( 1 ), the landscape seems to be crowded. (
  • In addition to the commercial, there are vaccine research and development considerations. (
  • Success in the endeavor would be a slam dunk for vaccine research, an area some drugmakers tend to shy away from because of the high risk and cost in development and low profits compared with other drugs and devices. (
  • FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. (
  • The technology that we're describing in this paper can be used to develop a vaccine against any virus, any parasite, any fungus, whereas this was never possible before the development of recombinant attenuated bacterial strains like those produced in our lab," Curtiss says. (
  • These results were presented by Dr. Niranjan Y. Sardesai, Inovio Sr. VP of Research and Development, at the Biochemical and Molecular Engineering XVII Conference in Seattle in a talk titled 'Engineering Effective Consensus DNA Vaccines. (
  • Inovio's SynCon technology enables rapid development of vaccines that can cover multiple subtypes simultaneously with a single formulation. (
  • In this review, we will explore the advances and hurdles involved in the development of more potent DNA vaccines. (
  • Since their development, vaccines have had an enormous impact on public health. (
  • Since then, recombinant DNA vaccines have emerged as promising tools for vaccine development against infectious agents, cancer, autoimmunity and even allergy [ 3 ]. (
  • The driving force for this decade-long effort [to create the new vaccine] has been the development of a simple delivery system for an HIV vaccine that can be administered without needles and that can be afforded by developing nations. (
  • Dose-sparing regimens and intradermal delivery have important implication for rapid clinical development of effective, well-tolerated and easy-to-distribute vaccines against MERS and other emerging coronaviruses. (
  • Intradermal delivery of synthetic DNA vaccines has significant advantages for rapid clinical development. (
  • The positive results of this study are important not only for the advancement of this MERS vaccine but also for development of other vaccines. (
  • For example vaccine action plan of WHO along with huge funding from international bodies were responsible for driving the vaccine market to great heights in the past and also resulted in development and expansion of vaccine production capacities especially in developing states notably India. (
  • The drug maker confirmed its presence in both the cell bank and the seed from which the vaccine is derived, suggesting its presence from the early stages of vaccine development, she said. (
  • The dose-sparing and immunogenicity-enhancing capabilities of the Vaxfectin(TM) adjuvant have been demonstrated in a range of vaccine applications in various animal models," said Alain P. Rolland, Pharm.D., Ph.D., Vical's Senior Vice President of Product Development, "but the potential safety and tolerability advantages of Vaxfectin(TM) compared with alternative DNA delivery enhancement options are making it our preferred choice for new development projects. (
  • The fact that Bill Gates has teamed up with the Department of Defense and DARPA, which is the special project research and development arm of the Pentagon, to develop a brand new type of vaccine which is being rushed into production is alarming to say the least. (
  • Many other vaccines, including those for chicken pox and rubella, are made using fetal tissue from two pregnancies terminated in the 1960s, for reasons unrelated to vaccine development. (
  • Several of the vaccines in use or advanced development for COVID-19 use the cell lines HEK-293 or PER.C6 for production. (
  • This Academy also called for the development of new vaccines that can be made by other means. (
  • Dr Laus said the vaccine could potentially be adapted in future to form a protective effect. (
  • To explain the protective effect of our DNA vaccines, we performed a CTL assay using splenocytes harvested from vaccinated/challenged animals and Hevc endothelial target cells (Hevc-Flk1), which endogenously expressed PDFGRβ and were stabley transfected with Flk1. (
  • Enhancing DNA vaccine potency remains a challenge. (
  • Since Edward Jenner's pioneering smallpox vaccine, vaccinology has followed an irregular path to its modern day form, with alternating periods of progress and stagnation ( 1 , 2 ). (
  • Could mRNA vaccines permanently alter DNA? (
  • Research on SARS-CoV-2 RNA by scientists at Harvard and MIT has implications for how mRNA vaccines could permanently alter genomic DNA, according to Doug Corrigan, Ph.D., a biochemist-molecular biologist who says more research is needed. (
  • The media's slanted coverage has provided a particularly fruitful public relations boost for messenger RNA (mRNA) vaccines - decades in the making but never approved for human use - helping to usher the experimental technology closer to the regulatory finish line. (
  • According to the Centers for Disease Control and Prevention (CDC) and most mRNA vaccine scientists , the buck then stops there - mRNA vaccines "do not affect or interact with our DNA in any way," the CDC says. (
  • The findings of the Harvard and MIT researchers also put the CDC's assumptions about mRNA vaccines on shakier ground, according to Corrigan. (
  • In fact, a month before the Harvard-MIT preprint appeared, Corrigan had already written a blog outlining possible mechanisms and pathways whereby mRNA vaccines could produce the identical phenomenon. (
  • In a second blog post , written after the preprint came out, Corrigan emphasized that the Harvard-MIT findings about coronavirus RNA have major implications for mRNA vaccines - a fact he describes as "the big elephant in the room. (
  • As many allready know, the new type of mRNA vaccines is sayed to change human DNA , and that is one reason why many opposes them, for safety reasons. (
  • Eurogentec S.A, Madison Vaccines Incorporated (MVI), Sanofi, Inovio Pharmaceuticals Inc and Novartis Ag are the leading market players in the global market. (
  • The leading companies in this market are Merck & Co, Madison Vaccines Incorporated (MVI), Glaxosmithkline Inc, Novartis Ag, Xenetic Biosciences Inc, Astellas Pharma Inc, Inovio Pharmaceuticals Inc and Vical Incorporated. (
  • [11] [12] En DNA-vaccine mod coronavirus er udviklet af firmaet Inovio. (
  • What Inovio has done with that product is prove that DNA- based approaches are safe and efficacious. (
  • A vaccine against cervical cancer, being developed by Inovio Pharmaceuticals Inc. of Blue Bell, Pa. (
  • Inovio Pharmaceuticals, Inc. announced that it has achieved compelling immune responses in a study of its multi-subtype DNA vaccine for foot-and-mouth (FMD) disease administered by its proprietary vaccine delivery technology in sheep, the second large animal in which this vaccine was evaluated. (
  • I am extremely proud of the INOVIO team, which has been working tirelessly to develop a safe and effective vaccine in the fight against the COVID-19 pandemic. (
  • Among the advantages, the vaccine would be more accessible and less expensive. (
  • This vaccine platform presents several attributes that confer distinct advantages over other vaccine technologies in terms of safety, ease of fabrication and stability. (
  • DNA vaccines have several distinct advantages, which include ease of manipulation, use of a generic technology, simplicity of manufacture, and chemical and biological stability. (
  • It was made in the Vaccine Pilot Plant at the NIAID's Vaccine Research Center (VRC). (
  • Early trials of this vaccine have been promising, so we look forward to seeing the results of this larger trial in men with advanced prostate cancer, a disease that urgently needs more effective therapies. (
  • If the vaccine performs well in trials and if the H5N1 virus evolves into a pandemic strain within the next couple of years, the vaccine could possibly be of some use in combating it, Nabel said. (
  • The federal government has a small stockpile of a traditional egg-based vaccine for H5N1, which has generated modest immune responses in trials. (
  • To Michael's mind, a DNA vaccine offers a promising short-term solution while an inactivated vaccine-which won't be tested in efficacy trials for at least 18 months but could be made in very large quantities at a lower cost-and other long-term solutions are still being developed. (
  • The vaccine is being developed for human trials as quickly as possible. (
  • He said, "The next step for this vaccine is phase III trials, after which the vaccine c ould receive government approval if all goes well. (
  • A prior clinical study conducted by the HIV Vaccine Trials Network (HVTN 080) using a fixed quantity of GENEVAX™ IL-12 equivalent to the high dose in the A5281 trial demonstrated that it effectively augmented responses to an experimental HIV pDNA vaccine delivered with EP in HIV-negative volunteers. (
  • [9] [10] Således har forskere på Statens Seruminstitut har fået tilladelse til at teste CoVAXIX, en DNA-vaccine mod coronavirus . (
  • April 9, 2021 ( Children's Health Defense ) - Over the past year, it would be all but impossible for Americans not to notice the media's decision to make vaccines the dominant COVID narrative, rushing to do so even before any coronavirus-attributed deaths occurred. (
  • While not claiming that vaccine RNA will necessarily behave in the same way as coronavirus RNA - that is, permanently altering genomic DNA - Corrigan believes that the possibility exists and deserves close scrutiny. (
  • Will the coronavirus help mRNA and DNA vaccines prove their worth? (
  • To our knowledge, this is the first demonstration of protection with an intradermally delivered coronavirus vaccine," said Ami Patel, Ph.D. , Caspar Wistar Fellow at the Vaccine & Immunotherapy Center and one of the lead authors of the paper. (
  • As of March 2017, at least 300 million vaccines have been given that were made using the WI-38 line alone. (
  • Vaccines that have been or are made using cell lines derived from fetal tissue include: Adenovirus Chicken pox Ebola Polio Rabies Rubella Shingles Of these, the vaccines approved for use in the United States include some of those against rabies (Imovax), rubella, chicken pox, shingles, and adenovirus (as of January 2017). (
  • Several approaches have been investigated including DNA vaccine engineering, co-delivery of immunomodulatory molecules, safe routes of administration, prime-boost regimen and strategies to break the immunosuppressive networks mechanisms adopted by malignant cells to prevent immune cell function. (
  • This comprehensive collection of chapters is the first of its kind in the rapidly moving field to provide an excellent update of all of the recent advances and, more importantly, the actual technical approaches to developing vaccines. (
  • A precise understanding of the genetic differences between closely related Mycobacteria suggests rational approaches to the design of improved diagnostics and vaccines. (
  • Researchers intend to conduct a full trial of the vaccine on about 30 patients across 10 British sites including Southampton and Surrey Universities, the Royal Marsden Hospital and a Cancer Research UK institute in Leeds. (
  • Because the vaccine, known as Prostvac, has been genetically modified researchers had to seek approval from the Department for Environment, Food and Rural Affairs, which assesses potential environmental and human health risks, as well as medical regulators for the trial to begin. (
  • Dr Kat Arney of Cancer Research UK said: "Many researchers around the world are investigating the potential of vaccines for treating cancer. (
  • Back in 1966, researchers extracted lung tissue from a 14-week aborted baby and developed a cell line from it known as MRC-5 that is still used in many vaccines today. (
  • SEATTLE -- Researchers at the University of Washington have developed a DNA vaccine they believe could last for years and supplement the flu shot. (
  • The researchers, in a study published in Nature Biotechnology , created a vaccine by engineering the vesicular stomatitis virus to incorporate a range of DNA from human melanoma cell lines. (
  • University of Leeds researchers, funded by Cancer Research UK, have used a library of DNA to create a vaccine that could be used to treat cancer, according to a study published in Nature Medicine. (
  • In addition, DNA vaccines are a great leveler among researchers around the world because they provide unprecedented ease of experimentation. (
  • Like many vaccine researchers, those at the Massachusetts Institute of Technology are exploring alternative DNA vaccines. (
  • MIT researchers created a patch made of many layers of polymers embedded with the DNA vaccine to deliver it to the skin, Manufacturing Chemist reports. (
  • Delivering DNA vaccines has been tricky for researchers. (
  • Researchers at the Johns Hopkins School of Public Health and Emory University have developed a DNA vaccine proven to protect against measles. (
  • Designing a vaccine that is both safe and effective presents a kind of Catch-22 for researchers. (
  • Through the assessment of a large panel of blood cytokines, researchers showed significant decrease in all mediators of inflammation, which further suggests the vaccine prevents the destructive inflammation induced by coronaviruses. (
  • The bacteria that go into bacterial vaccines can be grown in simple laboratory cultures. (
  • An EU-funded initiative has developed a fast and cost-effective approach that will allow using bacteria in feed to deliver vaccines. (
  • According to Dr Forlenza: "The use of food-grade lactic acid bacteria as a vaccine vehicle is an attractive strategy for delivering vaccines to the surface of mucosal membranes, which has never been investigated in fish. (
  • The breakthrough is in the modification of the bacteria in a way that allows them to enter fish cells and transfer a DNA plasmid to the cell itself not only in a petri dish, but also in living zebrafish larvae, leading to the expression of the vaccine antigen," Dr Forlenza points out. (
  • The project will benefit the fish vaccine and feed industry, following research to determine whether such bacteria can deliver DNA vaccines to the cells of a range of commercially important fish species. (
  • He said a batch of the bacteria can be grown in a matter of days, and purification and quality-control steps add a few weeks to the process of making the vaccine. (
  • It comprises a DNA sequence obtained from bacteria to shut down the T-helper (Th2) cells that trigger the body's inflammatory immune responses. (
  • However, because of the inability to preserve viable bacteria (such as by freezing), this live vaccine required continued passage, eventually resulting in a profusion of phenotypically different daughter strains that are collectively known as BCG. (
  • I spoke with Hong Jiang (cofounder and chief operating officer of Aegis Life, Inc.) in November 2020 to learn more about plasmid-DNA vaccines. (
  • In contrast to traditional vaccines, DNA-based vaccines can be rapidly manufactured and easily scaled, which drastically reduces the time to market. (
  • These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines. (
  • We then generated a human DNA vaccine incorporating the identified region of Tie-2 and used site directed mutagenesis to enhance the CD8 epitope. (
  • The types are further segmented into animal DNA vaccine and human DNA vaccine. (
  • The Global DNA vaccines market is predicted to grow at a CAGR of 41.89%, generating $xx million by the end of the forecast period of 2018-2026. (
  • The North America DNA vaccine market is predicted to flourish with a CAGR of 42.35% for the forecast period of 2018-2026, generating a market share of $XX million by 2026. (
  • Animal genetic vaccines are already present in the market. (
  • The large share of the market is attributed to government's initiatives to immunize citizens, coupled with high awareness regarding the benefits of genetic vaccines targeted towards animals. (
  • LineaRx posits that for the effectiveness of genetic vaccines or genetic immune therapies, transient expression may be sufficient. (
  • As protection against pancreas disease, Novartis developed a prophylactic DNA plasmid-based vaccine to be administered to salmon as naked plasmid in a single intramuscular injection. (
  • The first prostate cancer vaccine could be a step away after ministers gave their approval for a human trial of a new genetically modified therapy. (
  • In order to assess the legal status of the fish vaccinated with this new vaccine with regard to the legislation on genetically modified organisms, the European Commission suggested that the company carry out a scientific study on the integration/non-integration of the plasmid DNA into the fish genome. (
  • Jones explained the same elitist agenda in a show segment last week, saying, "They're marking you digitally and genetically with a virus and they have a vaccine that isn't even a vaccine, it goes in and reprograms your cells at the cellular level, taking control of the nucleus and mitochondria. (
  • Rather, it is a genetically engineered form of HPV genetic code that is added to the vaccines during their manufacture. (
  • The Sabine polio vaccine, manufactured by Merck, was contaminated with Simian virus-40 (SV-40), a virus known to cause cancer. (
  • In the 1950's and early 1960's, polio vaccines given to millions of children and adults used monkey kidney tissue cells contaminated with simian virus 40. (
  • A 1973 prospective study of more than 50,000 pregnancies concluded that inactivated polio vaccines given to pregnant women in that study between 1959 and 1965 were associated with excess malignancies and brain tumors in children born to those mothers. (
  • MRC-5 has admittedly been used to developed the Varivax vaccine for chicken pox, the ProQuad vaccines for both chicken pox and MMR (measles, mumps, and rubella), and several other vaccines for Hepatitis A, DTaP, Hib, polio, and rabies. (
  • One of the first medical applications of fetal tissues was their use in the production of the first polio vaccines. (
  • For example, in the 1950s, scientists at the Karolinska Institute in Sweden propagated a polio virus in fetal cells to make into a polio vaccine. (
  • Fuller said once a genetic code for a pathogen is known, scientists could design and produce a 'universal' vaccine in three months. (
  • The product is a therapeutic vaccine to be administered to dogs with stage II or stage III oral melanoma to aid in extending survival times. (
  • This study will provide important information as to the most adjuvant active dose of GENEVAX™ IL-12, and it will do so in combination with the Profectus therapeutic vaccine in HIV infected subjects. (
  • In this video, she speaks about the agenda to inject an experimental vaccine into everybody on the planet. (
  • A substantial amount of the text concentrates on the practical aspects of processing DNA, quality control and immunological responses. (
  • One of the vaccines is being evaluated in a Phase 1 human trial to assess the vaccine's safety and ability to generate immune responses in people. (
  • Env CE DNA also induced humoral responses able to recognize the full-length Env. (
  • Analysis of Env CE T cell responses in 16 macaques immunized with a mixture of DNA expressing full-length Env including HIV-1 BaL. (
  • Induction of immune responses by DNA vaccines in large animals. (
  • When applied to the skin, these particles produce good immune responses with much less DNA than is required by other routes, such as intramuscular or intradermal needle injection (5) . (
  • Our animal tests demonstrate that DNA vaccines made with synDNA(TM) technology are not only effective in eliciting robust immune responses, but also provide protection against dangerous pathogens. (
  • It has generally been assumed that DNA vaccines that produce more antigen in situ will elicit higher levels of immune responses. (
  • Dr. J. Joseph Kim, Inovio's president and CEO, said: 'We are pleased to demonstrate these robust DNA vaccine immune responses in a second globally-important farm animal impacted by foot-and-mouth disease. (
  • Among those, DNA vaccines are very promising, as they are able to elicit both humoral and cellular immune responses. (
  • As previously reported, the interim data from HVTN 080 show GENEVAX™IL-12 significantly increased the proportion of vaccine recipients that mounted antigen-specific CMI responses as compared to HIV pDNA alone. (
  • Seattle - A new study published in the September 2014 volume of the Journal of Public Health and Epidemiology reveals a significant correlation between autism disorder (AD) and MMR, Varicella (chickenpox) and Hepatitis-A vaccines. (
  • David D. Ho, scientific director of the Aaron Diamond AIDS Research Center, and Rockefeller's Irene Diamond Professor, along with his colleagues at Taiwan's Academia Sinica, has developed a DNA based vaccine that shows promise for halting most variations of H5N1 flu. (
  • The International AIDS Vaccine Initiative (IAVI) will fund testing of a new kind of preventive vaccine, which has been developed at the Institute for Human Virology (IHV), started in 1996 by Robert Gallo, M.D., at the University of Maryland. (
  • IAVI funds promising AIDS vaccines under intellectual-property agreements which will help make successful ones available at affordable prices to developing countries. (
  • New and increasingly sophisticated vaccines are taking aim at a broad range of disease-causing pathogens, targeting them with greater effectiveness at lower cost and with improved measures to ensure safety. (
  • Nevertheless, there are still a variety of pathogens for which vaccines are urgently needed. (
  • While such "optimized" vaccines elicited increased numbers of antigen-specific CD8+ T cells, these T cells had less anti-tumor activity in vivo. (
  • Jan 4, 2007 (CIDRAP News) - Federal officials have announced the launch of the first clinical trial of an H5N1 avian influenza vaccine made from a piece of the virus's DNA rather than from the whole virus, an approach that may facilitate faster vaccine production. (
  • Washington, DC, April 20, 2010 ( ) - A recent study by the Environmental Protection Agency (EPA) has confirmed 1988 as a "change point" in the rise of Autism Disorder rates in the U.S. - a date that pro-life leaders say correlates with the introduction of fetal cells for use in vaccines. (
  • According to the pro-life group Sound Choice Pharmaceutical Institute (SCPI), which specializes in vaccine research, that "environmental factor" may well be the use of aborted fetal cells in vaccines. (
  • The only environmental event correlating with these statistical autism trend 'change points' which would impact almost all children was the introduction of vaccines produced using human fetal cells and containing residual human DNA and cellular debris," said SCPI. (
  • Johnson & Johnson has selected a lead COVID-19 vaccine candidate from a number of options it has been working on since January. (
  • A new research collaboration between Dynavax Technologies and Clover Biopharmaceuticals aims to develop a vaccine candidate to prevent COVID-19. (
  • The frontrunner among DNA-based SARS-CoV-2 vaccines is Inovio's INO-4800 candidate. (
  • We have developed two DNA-based candidate vaccines ( 4 ), one of which is in preclinical evaluation. (
  • A similar vaccine candidate was previously shown to be safe and tolerable with a three-dose intramuscular injection regimen in a recently completed human phase 1 study and is currently in expanded studies of phase 1/2a trial. (
  • Dr. J. Joseph Kim, Inovio's President and CEO, said, 'Using our SynCon® technology we rapidly generated a synthetic vaccine candidate that shows promise as a preventive and treatment. (